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1. INTRODUCTION 
With the aging of the population, the need for the treatment of ocular diseases and disorders 
has become more important than ever. Increasingly high incidences of age-related macular 
degeneration, glaucoma, diabetic retinopathy and ocular inflammatory diseases demand better, 
more effective and innovative treatments. If we are to maintain the quality of life for this aging 
population, the preservation of vision is critical.  
Unfortunately, the ophthalmic formulations on the market suffer from poor bioavailability 
(< 2%) and it would be useful to design a new formulation which is able to prolong the residence 
time and reduce the administration frequency. Since topical ocular delivery treatments are 
considered to be the safest, least invasive and most self-administrable, their development is 
highly sought.  
The formulation of ocular drug delivery systems poses many challenges, but also offers many 
opportunities to overcome the inadequacies of the current formulations. The corneal epithelium 
has a complex hydro- and lipophilic character that limits drug absorption, and the eye has many 
protective mechanisms, including blinking, tear turnover and reflex lacrimation. There is 
therefore a need for the frequent instillation of eye drops, which is accompanied by discomfort 
and a decrease in patient compliance, especially in the long term.  
One way to overcome the natural anatomical barriers of the eyes is to take advantage of the 
mucosal layer and to formulate a drug delivery system with mucoadhesive properties. Polymer 
matrices which exhibit strong mucoadhesion are promising platforms in ocular drug delivery 
from the aspect of improved bioavailability.  
In my Ph.D. work, first (hyaluronic acid (HA) derivatives) and second generation (thiolated 
polymers) mucoadhesive polymers were characterized as potential ocular drug delivery systems. 
I carried out gel characterization (rheology) and determinations of mucoadhesion and drug 
release. Thiolated polymers, as new potential excipients in ophthalmic therapy, were 
characterized in a wide range.  
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2. LITERATURE SURVEY 
2.1. Possible drug delivery routes in the eye 
The main routes of ocular drug delivery system administration are topical, systemic/oral, 
periocular and intravitreal (Fig. 1). The most important processes in the eye are: trans-corneal 
permeation from the lacrimal fluid into the anterior chamber (Fig. 1, 1); non-corneal drug 
permeation across the conjunctiva and sclera into the anterior uvea (Fig. 1, 2); drug distribution 
from the blood stream via the blood–aqueous barrier into the anterior chamber (Fig. 1, 3); 
elimination of the drug from the anterior chamber by the aqueous humour turnover to the 
trabecular meshwork and Sclemm’s canal (Fig. 1, 4); drug elimination from the aqueous humour 
into the systemic uveoscleral circulation (Fig. 1, 5); drug distribution from the blood into the 
posterior eye across the blood–retina barrier (Fig. 1, 6); intravitreal drug administration (Fig. 1, 
7); drug elimination from the vitreous via the posterior route across the blood−retina barrier (Fig. 
1, 8); and drug elimination from the vitreous via the anterior route to the posterior chamber (Fig. 
1, 9) (Amo and Urtti, 2008; Almeida et al., 2014).  
 
Fig. 1. Routes of drug absorption and elimination (Amo and Urtti, 2008)  
 
In cases of topical application, eye drops, gels and ointments are used to target the anterior 
segment (cornea, conjunctiva, sclera, iris and ciliary body) of the eye. The most important 
benefits of this therapy are the non-invasiveness and administration by the patients themselves 
(Davis et al., 2004). Systemic delivery (oral) is non-invasive and very patient−compliant drug 
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administration, but unfortunately high dosage concentrations can be required, which can cause 
toxicity and side−effects (Gaudana et al., 2010). Periocular delivery (injections and implants in 
the eye) is more invasive and less patient−compliant, but more efficient, especially if the 
posterior segment of the eye is targeted (Ghate and Edelhauser, 2006). Intravitreal injections or 
implants are the most invasive forms of administration, which can involve several risks for the 
patient (haemorrhage or retinal detachment). For these reasons, the patient−compliance is very 
low, but higher concentrations of the active pharmaceutical ingredient (API) can be maintained 
in the retina or vitreous (Amo and Urtti, 2008; Lorentz and Sheardown, 2014).  
 
2.2. Challenges in ocular drug delivery formulation 
In ophthalmic therapy, there is an obvious need for more efficient formulations, but a number 
of factors must be taken into consideration, such as anatomical and biopharmaceutical aspects, 
patient-driven challenges and, not least, mandatory regulatory factors (Almeida et al., 2014; 
Lorentz and Sheardown, 2014).  
The anatomy of the eye poses considerable difficulties for ocular drug delivery. The most 
important anatomical barriers of the eye are the barriers responsible for drug removal from the 
ocular surface (blinking and the tear film) and the lacrimal fluid−eye barriers (the cornea and the 
conjunctiva) (Urtti, 2006; Ruponen and Urtti, 2015). The volume of a dispensed eye drop is 5-6 
times greater than the tear fluid volume on the ocular surface. During eye drop instillation, the 
fluid may flow out of the eye, followed by reflex blinking and a possibly increase in tear 
secretion, especially if the eye drop contains an irritant (Urtti and Salminen, 1993; Ghate and 
Edelhauser, 2006; Reimondez-Troitiño et al., 2015). Both the pH of the drug delivery system and 
the osmolality of the formulation must be similar to those of the natural tear film, as otherwise 
the formulation can cause increased tearing and irritation, resulting in poor therapeutic efficiency 
(Baeyens and Gurny, 1997). The corneal surface and conjunctiva are covered by a mucin coat, 
secreted by the goblet cells of the conjunctiva, with the functions of hydration, cleaning, 
lubrication and defence against pathogens. The corneal epithelium contains five cell layers, 
which are very well sealed, because the cells are joined by tight junctions and gap junctions, and 
they provide resistance against both hydrophilic and lipophilic active ingredients (Ghate and 
Edelhauser, 2006; Reimondez-Troitiño et al., 2015). Another possibility for drug removal is 
absorption of the drug into the systemic circulation (Urtti, 2006).  
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The biopharmaceutical-driven challenges involve the hydrophilicity or lipophilicity, and the 
size and the charge of the API. APIs with an amphiphilic character have the greatest chance of 
penetrating through the cornea and conjunctiva (Ahmed et al., 1987; Sasaki et al., 1995). The 
molecular mass of the drug and its delivery system plays important roles in the penetration 
(Sunkara and Kompella, 2003; Rabinovich et al., 2004). The components of the tears (buffers 
and proteins) must be taken into consideration during the formulation of a new ocular drug 
delivery system, because they can bind to the API and change its ionization state (Shell, 1982). 
All these physicochemical properties can affect the route and the rate of permeation in the 
cornea.  
The needs of patients must be satisfied by novel formulations. The optimum drug delivery 
system for patients must be effective, should require few applications per day and should be easy 
to handle and dispense; it must not cause local or systemic adverse events and only minimal or 
no visual interference, no ocular discomfort or foreign body sensation and no blockage of puncti 
or canaliculi; it must be as non-invasive as possible; and it must be inexpensive (Lorentz and 
Sheardown, 2014). Studies have shown that the more instillations or injections required and the 
more invasive the procedure, the greater the degree of patient non-compliance (Fig. 2) (Ghate 
and Edelhauser, 2006).  
 
Fig. 2. Possible drug delivery systems in the eye and their invasiveness, risk of complications 
and patient compliance 
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2.3. Regulatory considerations 
To launch an ophthalmic product, knowledge of the regulations is necessary. The regulation 
requirements of ophthalmic formulations have not been well defined, they differ considerably 
around the world and there is a need for mutual approvals. New drugs or delivery systems 
require human clinical trials in accordance with the Investigational New Drug Application in the 
United States or the Clinical Trial Notification in Europe (Ali and Lehmussaari, 2006).  
The European Commission has issued protocols for local toxicity and eye irritation 
measurements, in which the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay for the rabbit corneal epithelial (RCE) cell line is included. This test provides 
essential information on the biocompatibility of the measured API or excipients at a cellular level 
(DB-ALM, DataBase service on ALternative Methods to animal experimentation), which can be 
a basis of further in vivo experiments.  
During drug delivery formulation, it must be taken into consideration that excipients are 
neither inert nor inactive substances and they can also cause adverse reactions (Baldrick, 2000; 
Pifferi and Restani, 2003).  
As concerns the formulation requirements, The International Pharmacopoeia (Ph. Int. Fifth 
Edition, published by the WHO) includes a collection of recommended procedures for analysis 
and specifications for the determination of pharmaceutical substances, excipients and dosage 
forms. In connection with the definition of ophthalmic drops, the Fourth Supplement to the Fifth 
Edition of The International Pharmacopoeia specifies that the preparation of aqueous 
ophthalmic drops requires careful consideration of the need for isotonicity, a certain buffering 
capacity, the desired pH, the addition of antimicrobial agents and/or antioxidants, the use of 
viscosity-increasing agents, and the choice of appropriate packaging, which also correspond to 
the guidelines of the American Society of Hospital Pharmacists on Pharmacy-Prepared 
Ophthalmic Products (ASHP, 1993; The International Pharmacopoeia). Although tests of these 
factors are not listed in the regulatory directives, the manufacturers must fulfil them and these 
preformulation measurements are included in the Drug Master File or Applications (Ali and 
Lehmussaari, 2006).  
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2.4. Possible ways to increase the bioavailability of drugs in topical ophthalmic therapy 
Numerous strategies have been developed to improve topical ocular bioavailability. The most 
common are eye ointments, prodrugs, penetration enhancers, liposomes, niosomes, 
nanoparticles, nanospheres, nanosuspensions, microemulsions and viscosity enhancers 
(mucoadhesive polymers, gels and in situ forming gels) (Lorentz and Sheardown, 2014; 
Reimondez-Troitiño et al., 2015).  
The use of mucoadhesive drug delivery system prolongs the contact time between the 
preparation and the corneal/conjunctival epithelium (Ludwig, 2005; Patel et al., 2010, Ruponen 
and Urtti, 2015). The mucoadhesive polymers can be classified into two main categories: first 
and second generation mucoadhesive polymers (Smart, 2005; Andrews et al., 2009; Serra et al., 
2009; Carvalho et al., 2010; Karolewicz, 2015).  
 
2.4.1. First generation mucoadhesive polymers 
The first-generation mucoadhesive polymers are natural or synthetic hydrophilic molecules, 
which can be anionic, cationic or non-ionic. These polymers are considered to be non-specific 
mucoadhesive systems, because the adhesion may occur at sites other than expected.  
Anionic polymers are used in pharmaceutical formulations, thanks to their mucoadhesivity 
and low toxicity. These polymers are characterized by the presence of carboxyl and sulfate 
functional groups. They include poly(acrylic acid), sodium carboxymethylcellulose, 
polycarbophil, carbomer, alginates, hyaluronic acid, etc.  
Cationic polymers are able to bind to mucus via ionic interactions, thanks to the negatively 
charged surface of the mucus layer in addition to hydrogen−bonding. The most widely studied 
cationic polymer is chitosan.  
Non−ionic polymers are weaker mucoadhesives as compared with the anionic and cationic 
polymers. This group of polymers includes hydroxypropylmethylcellulose, 
hydroxyethylcellulose (HEC) and methylcellulose (Andrews et al., 2009; Serra et al., 2009; 
Carvalho et al., 2010; Karolewicz, 2015).  
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2.4.2. Second generation mucoadhesive polymers 
The second-generation mucoadhesives are derivatives of the first-generation polymers (e.g. 
thiolated polymers) and include several new mucoadhesives (e.g. lectins and bacterial adhesives) 
(Andrews et al., 2009; Serra et al., 2009).  
Lectins are naturally present proteins that play a fundamental role in biological recognition 
phenomena (cells and proteins). They are glycoproteins which are able to bind non-covalently to 
glycosylated components of the cellular membrane, but not of the mucus, and adhesion can 
therefore be called cytoadhesion. The disadvantages of these systems are their toxicity and 
immunogenicity and they can induce antibodies, which can render individuals susceptible to 
systemic anaphylaxis on subsequent exposure (Andrews et al., 2009; Han et al., 2015).  
The function of bacterial adhesions is based on the phenomenon of the pathogenic bacteria 
adhering to the mucosal membranes in the gastrointestinal tract. K99−fimbriae (from E. coli) are 
covalently attached to polyacrylic acid networks, which increase the in vitro adhesion relative to 
the unmodified polymer, through the adhesion to the epithelial surface of the erythrocytes (Serra 
et al., 2009; Carvalho et al., 2010).  
Thiolated polymers (thiomers) are mucoadhesive polymers with thiol group-containing side-
chains (Bernkop-Schnürch, 2005). The most commonly used thiomers are synthetized from 
chitosan, alginate, polyacrylates and cellulose derivatives (Andrews et al., 2009). In contrast with 
the first-generation polymers, they are capable of forming covalent (disulfide) bonds with 
cysteine-rich subdomains of the mucus layer (Bernkop-Schnürch, 2005).  
Other advantages of thiomers include permeation enhancement through the reversible opening 
of the tight junction, enzyme inhibition and efflux pump inhibition (Iqbal et al., 2011; Rahmat et 
al., 2012; Gradauer et al., 2013). As a result of these advantages, these polymers ensure the 
prolongation of the residence time and increase the bioavailability. They can be used in many 
medical fields (e.g. topical ocular therapy) in various dosage forms, such as liquid drops, gels or 
mini-tablets (Bernkop-Schnürch, 2005).  
Earlier studies (Marschutz and Bernkop-Schnürch, 2002; Bernkop-Schnürch et al., 2003) 
revealed the lower stability of thiolated polymers in solution, thanks to thiol oxidation at pH ≥ 6. 
During the oxidation process, inter- and intramolecular disulfide bonds are formed, limiting the 
permeation enhancement and mucoadhesivity of the solutions. At higher pH of the thiomer 
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solution, the thiol groups are oxidized more rapidly, thanks to the decrease in H
+
 concentration 
leading to an increase of the negative thiolate anions, S
−
, which are more capable of oxidation. 
There are two ways for the stabilization of thiolated polymers in solution: 1) the use of 
reducing agents (antioxidants) or 2) thiol group protection by already−formed disulfide bonds 
(Marschutz and Bernkop-Schnürch, 2002; Bernkop-Schnürch et al., 2003; Dünnhaupt et al., 
2012).  
The addition of a reducing agent during or after synthesis ensures the stability of thiol groups 
in solution, providing free thiol groups for better mucoadhesion and permeation. In earlier 
studies 2-mercaptoethanol (Bernkop-Schnürch et al., 2003), dithiothreitol (DTT), sodium 
borohydride (Bernkop et al., 2004), hydroxylamine (Kafedjiiski et al., 2005), EDTA (Martien et 
al., 2011) and sodium cyanoborohydride (Rahmat et al., 2011) were used to avoid the oxidation 
of thiol groups.  
In the case of thiol group protection, thiol groups are protected by already−formed disulfide 
bonds. In earlier studies, this type of protection was performed with pyridyl sulfhydryl 
(Dünnhaupt et al., 2012), 6-mercaptonicotinamide (Dünnhaupt et al., 2012, Laffleur et al., 2015), 
2-mercaptonicotinamide (Wang et al., 2012; Hintzen et al., 2013) or 3-methyl-1-phenylpyrazole-
5-thiol (Müller et al., 2013). Thanks to the addition of these protective agents, the thiolated 
polymers have improved stability and mucoadhesive, enzyme-inhibitory, permeation-enhancing 
and efflux-pump inhibiting properties (Dünnhaupt et al., 2012). The disadvantage of this method 
is the longer synthesis. 
 
2.5. Mucoadhesion 
One of the most important phenomena in ocular formulations is the adhesion between the 
drug delivery system and the eye tissues. In bioadhesion, physical or chemical bonds are formed 
between the biological and synthetic surfaces. Mucoadhesive drug delivery vehicles exploit the 
adhesion between the polymer component and the biological tissue, a mucosal membrane, the 
mechanism being referred to as mucoadhesion (Chickering and Mathiowitz, 1999). In the case of 
the ocular mucus, the conjunctival goblet cells, the conjunctival epithelium and the corneal 
epithelium are responsible for the secretion of mucin. Mucins are large glycoproteins which are 
mainly composed of a protein core and carbohydrates and are well glycosylated. There are two 
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types of ocular mucins: membrane-associated and secreted mucins (Lorentz and Sheardown, 
2014; Ruponen and Urtti, 2015).  
The new delivery systems with mucoadhesive properties have various advantages: better 
bioavailability, a lower active ingredient concentration is sufficient and the administration 
frequency can be decreased, thanks to the enhanced residence time (Saettone et al., 1985; 
Andrews et al., 2009).  
The mechanisms governing mucoadhesion are determined by the intrinsic properties of the 
formulation and by the environment in which it is applied. The polymer properties include its 
molecular mass, the presence of functional groups, the chain flexibility, the concentration, the 
degree of cross-linking and the degree of hydration. The environmental-related factors are the 
pH, the initial contact time, the swelling and the physiological variations (Leung and Robinson, 
1990; Robinson and Mlynek, 1995; Leitner et al., 2003; Ludwig, 2005; Andrews et al., 2009; 
Carvalho et al., 2010).  
 
2.5.1. Mechanism of mucoadhesion 
Mucoadhesion can be described in three steps: 1) the formation of an intimate contact 
between the mucoadhesive preparation and the mucus, followed by the wetting of the 
mucoadhesive formulation; 2) the swelling of the macromolecules and the formation of an 
interpenetrating network with the mucus macromolecules; and 3) chemical bond formation 
(primary or secondary) between the entangled chains (Duchêne et al., 1988; Caramella et al., 
2015).  
Physical and chemical interactions can arise during the process of mucoadhesion. Physical 
interactions may occur during the interpenetration of the polymer chains into the mucin layers, 
and primary (covalent) and secondary chemical bonds (i.e. ionic bonds, hydrogen-bonds and van 
der Waals interactions) can evolve between the entangled chains (Dodou et al., 2005).  
 
2.5.2. Mucoadhesion theories 
Numerous theories have been put forward to explain the complex phenomenon of 
mucoadhesion, such as electronic, adsorption, wetting, diffusion and fracture theories. It is 
difficult to compare these theories, but they may well supplement each other and reflect the 
complex nature of mucoadhesion (Fig. 3).  
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The electronic theory is based on the different electronic structures of the polymer and mucin; 
it follows that a double layer of electrical charge is formed on the interface, the attractive forces 
within this electronic double layer determining the mucoadhesive strength.  
The adsorption theory is based on the formation of van der Waals interactions, hydrogen-
bonds, etc. Such forces have been considered the most important in the adhesive interaction 
phenomenon because, although they are individually weak, a great number of interactions can 
result in intense global adhesion. 
The wetting theory relates to the ability of the mucoadhesive polymer to spread over a tissue. 
The general rule states that the lower the contact angle, the greater the affinity.  
 
Fig. 3. Mucoadhesion theories (Dodou et al., 2005)  
 
The most important step in the diffusion theory is the interpenetration of the polymer chains 
into the mucus. It is believed that the adhesion force increases with the degree of penetration of 
the polymer chains. In order for diffusion to occur, it is important that the components involved 
should have good mutual solubility, which means that the bioadhesive and the mucus should 
have similar chemical structures.  
The fracture theory analyses the forces required to separate the two surfaces after adhesion.  
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The mechanical theory assumes that adhesion arises from the interlocking of a liquid adhesive 
into the irregularities on the rough surfaces, and provides an increased surface area available for 
interaction together with an enhanced viscoelastic and plastic dissipation of energy during joint 
failure, which are thought to be more important than a mechanical effect in the adhesion process 
(Chickering and Mathiowitz, 1999; Smart, 2005; Serra et al., 2009; Carvalho et al., 2010).  
 
2.6. Experimental aims 
In ophthalmic drug delivery systems, the polymers applied play an important role in the 
increase of the bioavailability. The use of mucoadhesive polymers can increase the residence 
time on the ocular surface or in the cul-de-sac. For this reason, it is very important to determine 
the mucoadhesive properties of the polymers. Since these polymers are planned to be used in 
ophthalmic therapy, the matrix also has to be characterized with regard to its potential for drug 
release.  
In my Ph.D. work, I characterized hyaluronic acid derivatives as first generation and thiolated 
poly(aspartic acid) (ThioPASP) polymers as second generation mucoadhesive polymers, as 
potential vehicles for ocular drug delivery systems.  
The aims of my experimental work can be summarized as follows (Fig. 4):  
 Comparisons of a nanosized cross-linked sodium salt (CLNaHA), a linear sodium salt 
(NaHA) and a linear zinc salt of hyaluronic acid (ZnHA): 
o investigation of their biocompatibility, 
o rheological characterization of the matrix of the HA derivatives,  
o mucoadhesion determination:  
 in vitro (rheology and tensile test) measurements, 
 ex vivo (tensile test) measurements,  
o drug release profile determination.  
 Characterization of ThioPASP as a potential new type of excipient in ophthalmic therapy: 
o preformulation measurements from the aspect of ophthalmic drug delivery system 
formulation,  
o investigation of biocompatibility, 
o polymer matrix characterization: 
 swelling capability, 
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 rheological properties, 
o determination of mucoadhesion: 
 in vitro (rheology and tensile test) measurements, 
 ex vivo (tensile and ‘wash away’ test) measurements,  
o drug release profile determination, 
o determination of the effects of the stabilizing agents (dithiothreitol, glutathione and 
acetylcysteine stabilization) on the properties of the ThioPASP polymers:  
 determination of mucoadhesion (rheology and tensile test), 
 drug release profile determination. 
 
Fig. 4. Measurements performed with first and second generation mucoadhesive polymers 
 
3. MATERIALS AND METHODS 
3.1. Materials 
A phosphate-buffered saline (PBS) solution of pH = 7.4 was prepared by dissolving 8 g dm
-3
 
NaCl, 0.2 g dm
-3
 KCl, 1.44 g dm
-3
 Na2HPO4·2H2O and 0.12 g dm
-3
 KH2PO4 in distilled water, 
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the pH being adjusted with 0.1 M HCl. Lacrimal fluid of pH = 7.4 was prepared by dissolving 
2.2 g dm
-3
 NaHCO3, 6.26 g dm
-3
 NaCl, 1.79 g dm
-3
 KCl, 96.4 mg dm
-3
 MgCl2.6H2O and 
73.5 mg dm
-3
 CaCl2·H2O in distilled water, the pH being adjusted with 1 M HCl.  
2,2-(Ethylenedioxy)bis(ethylamine), 1-[3(dimethylamino)propyl]-3-ethylcarbodiimide 
methiodide, mucin (porcine gastric mucin type II), MTT, HBSS (Hank’s Buffered Salt Solution), 
dimethyl sulfoxide, sodium diclofenac (SD) and sodium fluorescein were purchased from Sigma 
Aldrich (USA). Mucin dispersions were prepared with PBS or simulated lacrimal fluid and 
stirred for 8 h. HEC (Natrosol Pharm) was bought from Hercules.  
 
3.1.1. Hyaluronic acid derivatives 
NaHA (Mw: 4350 kDa) and ZnHA (Mw: 498 kDa) were purchased from Richter Gedeon Ltd. 
(Budapest, Hungary), and CLNaHA was prepared by BBS Biochemicals LLC (Debrecen, 
Hungary).  
As topical use, HA is applied in the treatment of dry eye and Sjögren’s syndrome. In higher 
concentrations, with a gel-like structure, HA can be used to prevent the desiccation of the cornea 
and it can be utilized as a carrier for antibiotics to the eye, because a formulation with relatively 
high viscosity and mucoadhesive properties prevents the drug from being washed out by the tears 
and the drug release is therefore prolonged (Price et al., 2007; Vasi et al., 2014). 
In earlier studies, nano-sized CLNaHA was prepared by a carbodiimide technique, based on 
covalent cross−linking via the carboxyl groups of the HA chain with a diamine in aqueous 
medium at room temperature. Through cross−linking of the HA molecule, the degradation time 
can be prolonged and the mechanical stability can be improved (Kafedjiiski et al., 2007; Bodnár 
et al., 2009; Maroda et al., 2011; Berkó et al., 2013; Vasi et al., 2014).  
Another HA modification involves ZnHA complex formation by adding Zn(II) chloride to an 
aqueous NaHA solution at pH 5.5-6.5. Beside the typical HA effects, ZnHA has scavenging, 
bactericidal, bacteriostatic and fungicidal effects, which are useful in ocular therapy, because the 
traditional preservative may then be omitted from the formulation (Nagy et al., 1998; Illés et al., 
2002).  
Gels of CLNaHA, NaHA and ZnHA were prepared in concentrations of 0.5, 1 and 2% w/w. 
The samples were stored at 4 °C and were used for the measurements after 3 days.  
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3.1.2. Thiolated poly(aspartic acid) polymers 
In our work, thiol-containing side-groups were bonded to poly(aspartic acid) (PASP). PASP 
polymers were synthetized by the Soft Matters Group at Budapest University of Technology and 
Economics (Fig. 5). PASP is a biocompatible and biodegradable polymer by virtue of its protein-
like structure, and its degradation products are excreted by the physiological mechanisms of the 
body. It is not toxic and does not generate immunogenicity. In in vitro and ex vivo experiments, 
1 M NaBrO3 solution was used as a model oxidant (Gyenes et al., 2008; Gyarmati et al., 2013; 
Gyarmati et al., 2014).  
The following reducing agents were used as antioxidants during the synthesis: dithiotreitol 
(Merck), glutathione (Merck) and N-acetylcysteine (Reanal Hungary). 
 
 
Fig. 5. a) Reaction of reversible thiol-disulfide exchange; b) oxidation−induced sol-gel transition 
(Gyarmati et al., 2013) 
 
3.2. Methods 
3.2.1. Preformulation measurements 
Osmolality, surface tension, refractive index and transmittance were measured in aqueous 
solutions of ThioPASP at five concentrations (1, 3, 5, 7 and 10% w/w).  
Osmolality measurements were carried out with an automatic osmometer (Knauer Semi-micro 
Osmometer, Germany) by measurement of the freezing point depression of the solution.  
Surface tension measurements were performed with the OCA Contact Angle System 
(Dataphysics OCA 20, Dataphysics Inc., GmbH, Germany), using the pendant drop method. The 
Young-Laplace equation was used for the calculation of surface tension (OCA Manual).  
Refractive index was measured with an Abbe refractometer.  
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The pH of ThioPASP solutions prepared with distilled water and PBS was determined with a 
pH-meter (Testo 206-pH2, UK).  
Optical tests were performed by the measurement of transmittance with a UV-
spectrophotometer (Unicam Heλios α Thermospectronic UV-spectrophotometer v4.55, UK) in 
the wavelength range 200-600 nm (Budai-Szűcs et al., 2015).  
 
3.2.2. Cytotoxicity 
For the cytotoxicity measurements, MTT tests were performed on the RCE cell line by a 
method described previously (Sandri et al., 2012; Mori et al., 2014; Horvát et al., 2015a,b). 
CLNaHA, NaHA and ZnHA formulations of 4% w/w were used in 20-fold dilution. ThioPASP 
solutions were measured in concentrations of 5, 7 and 10% w/w. All samples were brought into 
contact with cells for 3 h.  
 
3.2.3. Rheology 
The rheological properties were studied with a Physica MCR101 rheometer (Anton Paar, 
Austria). The tests were performed by a method described previously (Horvát et al., 2015a,b,c; 
Budai-Szűcs et al., 2015).  
Measurements were carried out with CLNaHA, NaHA and ZnHA gels with and without 
mucin (the final mucin concentration in the mixtures was 5% w/w). Flow curves and viscoelastic 
character were determined. Measurements were made over the frequency range from 0.01 to 
100 Hz, whereby the storage modulus (G’), loss modulus (G”) and complex viscosity (η*) were 
determined.  
ThioPASP was dissolved in PBS and gelation was initiated by the addition of oxidant 
(20% w/w). The precursor solutions of the hydrogels consisting of the ThioPASP and oxidant 
were mixed on the plate of the rheometer. Measurements were performed with and without 
mucin (the final mucin concentration in the mixtures was 5% w/w). The gelation and the 
viscoelastic character (frequency sweep tests) were made over the angular frequency range from 
0.1 to 100 s
-1
, whereby G’, G” and η* were determined. In order to investigate the effect of 
blinking on the gel structure, accelerated blinking cycles were applied by using the automation 
function of the instrument. Tests were performed at 10% w/w ThioPASP.  
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3.2.3.1. Rheological data analysis  
Rheological synergism between mucin and polymer mixtures can be proposed as an in vitro 
parameter through which to determine the mucoadhesive behaviour of polymers (Hassan and 
Gallo, 1990). The rheological method is based on the determination of the changes in rheological 
parameters after the mucoadhesive polymer is mixed with mucin. Hassan and Gallo 
demonstrated that a synergistic increase in viscosity could be observed when the mucoadhesive 
polymer and mucin were mixed together. This viscosity change, called the bioadhesive viscosity 
component (𝜂𝑏), is caused by chemical and physical bonds formed in mucoadhesion. It can be 
calculated as follows:  
 𝜂𝑏 = 𝜂𝑡 − 𝜂𝑚 − 𝜂𝑝  (1) 
where 𝜂𝑡 is the viscosity of the mucin-polymer solution system, and 𝜂𝑚 and 𝜂𝑝 are the viscosity 
components of the mucin and polymer solutions (Hassan and Gallo, 1990; Caramella et al., 
1999; Marschütz and Bernkop-Schnürch, 2002). 
More recently, the rheological synergism parameters have been measured by dynamic 
oscillatory rheometry. In this case, the absolute synergism parameters (∆𝐺′ and ∆𝜂∗) can be 
calculated as follows (Madsen et al., 1998):  
 ∆G' = G'(mix) - (G'(polymer) +  G'(mucin))  (2) 
 ∆η* =  η(mix) 
* - (η(polymer)
* +  η(mucin)
* )  (3) 
where mix is the polymer-mucin mixture.  
If the calculated synergism parameters are negligible, it is reasonable to use the relative 
rheological synergism parameters (∆𝐺𝑟𝑒𝑙
′  and ∆𝜂𝑟𝑒𝑙
∗ ), which express the relative increments in 
viscoelasticity with regard to the polymer (𝐺(𝑝𝑜𝑙𝑦𝑚𝑒𝑟)
′  and 𝜂(𝑝𝑜𝑙𝑦𝑚𝑒𝑟)
∗ ) and mucin 
(𝐺(𝑚𝑢𝑐𝑖𝑛)
′  and 𝜂(𝑚𝑢𝑐𝑖𝑛)
∗ ) solutions alone (Madsen et al., 1998; Horvát et al., 2015c): 
 ∆Grel
' =  
∆G'
G(polymer)
' +G(mucin)
'    (4) 
 ∆ηrel
* =  
∆η*
η(polimer)
* +η(mucin)
*    (5) 
3.2.4. Swelling 
The water absorption capacity of the ThioPASP gels was determined gravimetrically by a 
method described previously (Horvát et al., 2015c). 20% w/w mixtures of ThioPASP with 
oxidant (1 M NaBrO3, 20% w/w) were measured.  
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3.2.4.1. Swelling data analysis 
The percentage swelling (% S) gives information on the water uptake capacity of the polymer, 
which can be calculated from the following equation:  
   % 𝑆 =  
𝑀𝑡−𝑀0
𝑀0
 × 100  (6) 
where M0 is the mass of the dry gel (g) and Mt is the mass of the swollen gel (g).  
Another important factor involved in the swelling process is the swelling power (Fswp), which 
gives information concerning the mechanism of the swelling:  
 𝐹𝑠𝑤𝑝 =
𝑀𝑡−𝑀0
𝑀0
= 𝐾𝑡𝑛  (7) 
where t is time (min). The swelling constants (K) and the swelling exponents (n) can be 
determined by power law fitting to the curve of Fswp vs. t (min).  
The mechanism of water uptake is indicated by the value of n. A value in the range 0.45-0.5 
corresponds to Fickian diffusion, while a value of 0.5-1 means that the diffusion mode is non-
Fickian (Karadağ et al., 2002). 
 
3.2.5. Tensile test 
Tensile tests were performed with a TA-XT Plus (Texture analyser (ENCO, Spinea,I)) 
instrument equipped with a 1 kg load cell and a cylinder probe with a diameter of 1 cm. Samples 
were placed in contact with a filter paper disc wetted with 50 µl of 8% w/w mucin dispersion (in 
vitro), simulated lacrimal fluid (blank) or excised porcine conjunctiva (ex vivo).  
The measurements were performed by a method described previously (Horvát et al., 
2015a,b,c).  
  
3.2.5.1. Tensile test data analysis 
In the tensile test, the normalized mucoadhesion parameters (ΔAUC/AUC) were calculated as 
followed (Salcedo et al., 2012):  
 
∆AUC
AUC
=  
AUCm-AUCb
AUCb 
   (8) 
where AUCm is the work of adhesion in presence of mucin and AUCb is the work of adhesion of 
blank measurements (with simulated lacrimal fluid).  
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3.2.6. ‘Wash away’ measurement 
To perform the ‘wash away’ measurements, an earlier-developed modified Franz diffusion 
cell was used (Bonferoni et al., 1999; Rossi et al., 1999). The measurements were performed by 
a method described previously (Horvát et al., 2015c). Ex vivo tests were made on excised porcine 
conjunctiva placed on the acceptor chamber and simulated lacrimal fluid was streamed through 
the donor chamber. 250 mg of polymer gel (5, 7 or 10% w/w) was used, with sodium fluorescein 
(0.008% w/w) as the measured marker. HEC gels under the same experimental conditions were 
used as reference.  
 
3.2.7. Drug release 
The drug release profile of SD was determined with a vertical Franz diffusion cell system 
(Hanson Microette Plus TM). 1% w/w formulations of CLNaHA, NaHA or ZnHA and 7 and 
10% w/w ThioPASP gel concentrations were prepared. All samples contained 0.1% w/w SD. 
The measurements were performed by a method described previously (Horvát et al., 2015a,b,c).  
 
3.2.7.1. Drug release data analysis 
The swelling-controlled drug release mechanism can be characterized with the following 
equation:  
 
Mt
M∝
= ktn  (9) 
where Mt M∝⁄   is the fraction of drug released, k is the kinetic constant and n is the release 
exponent describing the mechanism of the release. These values can be determined from the 
equation of the power law fitted to the curve of the amount of drug released (% w/w) against 
time (min).  
An n value in the range 0.45-0.5 corresponds to Fickian diffusion, while a value of 0.5-1 
means that the diffusion mode is non-Fickian (Peppas et al., 2000).  
 
3.2.8. Statistical analysis 
The results were evaluated and analysed statistically with GraphPad Prism version 5 software. 
Two-way ANOVA analysis was applied with Bonferroni post-tests (Patterson et al., 2010). The 
values are expressed as means ± standard deviation (SD). A level of p ≤ 0.05 was taken as 
significant, p ≤ 0.01 as very significant, and p ≤ 0.001 as highly significant.  
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4. RESULTS AND DISCUSSION 
4.1. First generation mucoadhesive polymers 
4.1.1. Rheology of the gels 
The viscoelastic characters of CLNaHA, NaHA and ZnHA were determined by frequency 
sweep testing in the frequency range 0.1 to 100 Hz. Figure 6 depicts the frequency sweep test 
results on the measured samples at 1% w/w polymer concentration.  
 
 
 
Fig. 6. G’ (solid symbols) and G” (open symbols) values of ( ) CLNaHA, ( ) NaHA and ( ) 
ZnHA as a function of frequency 
 
The highest moduli values were observed for NaHA, which corresponds to its long linear 
structure. CLNaHA exhibited lower values, because it contains intrachain cross-linking, which 
produces nanoparticles with a particle size < 110 nm (Maroda et al., 2011), and ZnHA had the 
lowest viscosity. The structure of the ZnHA molecules in the formulation probably involves 
fewer entanglements, and this causes the lower viscosity.  
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CLNaHA and NaHA displayed viscoelastic behaviour, acting as viscous solutions in the 
lower frequency range, and demonstrating elastic properties at higher frequency. The cross-over 
point for NaHA was seen at lower frequency than that for CLNaHA, from which it can be 
concluded that CLNaHA shows less elastic behaviour. In contrast with CLNaHA and NaHA, 
ZnHA behaves as a viscous fluid; G” predominates over G’, and no cross-over point can be 
detected.  
This viscoelastic behaviour of the derivatives is very beneficial for purposes of ocular 
therapy, because they can easily spread over the eye surface during blinking and prolong the 
residence time of the drug delivery system.  
 
4.1.2. Cytotoxicity 
Figure 7 illustrates the results of the biocompatibility determination of CLNaHA, NaHA and 
ZnHA on RCE cells by the MTT test. As control, HBSS was used.  
 
 
Fig.7. Biocompatibility of CLNaHA, NaHA and ZnHA formulations 
 
CLNaHA and NaHA are biocompatible: the cell viability was 90.84 ± 9.90% in the case of 
CLNaHA and 103.90 ± 6.56% in the case of NaHA; ZnHA displayed lower biocompatibility the 
(cell viability after a 3 h contact time was 54.39 ± 11.91%). 
Under in vivo conditions, zinc is non-toxic, thanks to the homeostatic regulatory mechanisms. 
The maintenance of homeostasis in cell lines is difficult, which leads to a decrease in cell 
viability. It was established earlier that tolerance to zinc can be dependent on the rate of zinc 
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uptake and the capacity of the protective mechanism (Borovansky and Riley, 1989; Ugarte and 
Osborne, 2001; Bozym et al., 2010; Mehr, 2011; Ugarte et al., 2013).  
Our results demonstrate that CLNaHA and NaHA are biocompatible. Although ZnHA 
exhibits lower biocompatibility in the RCE cell line, under in vivo conditions it may have better 
biocompatibility thanks to the in vivo homeostatic mechanisms.  
 
4.1.3. Mucoadhesion 
4.1.3.1. Rheology 
Measurements were performed at three different concentrations; 0.5, 1 and 2% w/w. Flow 
curves of the CLNaHA, NaHA and ZnHA formulations and their mixtures with mucin are 
presented in Fig. 8.  
 
 
Fig. 8. Flow curves of CLNaHA (a), NaHA (b) and ZnHA (c) at ( ) 0.5% w/w, ( ) 1% w/w and 
( ) 2% w/w, with mucin (open symbols) or without mucin (solid symbols)  
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The measured derivatives and their mixtures with mucin displayed shear-thinning behaviour, 
with the shear viscosity dependent on the degree of shear load and the flow curve exhibiting a 
decreasing slope, which is typical for polymer systems (Mezger, 2002).  
Mucoadhesive behaviour was observed for all formulations at all three concentrations. The 
shear stress values of the mixtures (gel and mucin) were higher than those of the HA derivatives 
without mucin. These results correspond to the phenomenon that interactions can occur between 
the polymers and mucin. Mucin has a gel-strengthening effect, because more network links are 
created by entanglements and secondary bond (hydrogen-bond) formation. The calculated 
absolute synergism parameters (Eq. 3; section 3.2.3.1) of viscosity at a shear rate of 100 s
-1
 are 
illustrated in Fig. 9.  
 
 Fig. 9. Calculated absolute synergism parameter values of viscosity at a shear rate of 100 s
-1
  
 
The calculated values revealed that the mucoadhesive behaviour increased with increase of 
the polymer concentration. At higher concentration, an adequate gel structure is probably 
formed, which can easily interpenetrate and form secondary bonds with the mucin. CLNaHA is a 
nanoparticulate system which contains intrachain cross-linking, enabling the CLNaHA 
molecules to interpenetrate more easily than the other two derivatives at all three concentrations. 
At 0.5% w/w, CLNaHA exhibited more marked mucoadhesion than those of NaHA and ZnHA, 
which is very beneficial in the case of eye drops for instillation. ZnHA at lower concentrations 
has a liquid-like structure, which causes difficulty in interpenetration, while at higher 
concentration (2% w/w) it has a gel-like structure and its mucoadhesive behaviour is similar to 
those of the other derivatives. At 1 and 2% w/w, there is not a significant difference in the 
mucoadhesivity of CLNaHA and NaHA.  
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The results of rheological measurements indicated that CLNaHA, NaHA and ZnHA are 
mucoadhesive, especially at higher polymer concentration. The pronounced mucoadhesive 
nature of CLNaHA at 0.5% w/w is very advantageous in ocular therapy, because the washing-out 
from the eye by lacrimation after instillation demands more effort as compared with formulations 
without mucoadhesive polymers. Thanks to the mucoadhesive and viscoelastic behaviour of 
CLNaHA, NaHA and ZnHA, they are able to prolong the residence time on the ocular surface.  
 
4.1.3.2. Tensile test 
The tensile test involves measurement of the force of detachment and the total work of 
adhesion needed to separate the surfaces, which results from the area under the force−distance 
curve (Woertz et al., 2013). Earlier studies established the dependence of the adhesive force of 
chemical bond formation between the polymers and mucin, whereas the work of adhesion is 
dependent not only on chemical bond formation, but also on physical mechanisms 
(entanglements and interpenetration) (Park and Munday, 2002; Vasir et al., 2003).  
The adhesive force (F) and the work of adhesion (A) of CLNaHA, NaHA and ZnHA were 
determined in contact with mucin (Fig. 10). 
 
 
Fig. 10. Adhesive force (a) and work of adhesion (b) of ( ) CLNaHA, ( ) NaHA and ( ) ZnHA 
as a function of the concentration of the polymer in contact with mucin (***: p ≤ 0.001 highly 
significant compared with CLNaHA and NaHA) 
 
The values of F for all three derivatives did not increase with increase of the concentration. 
Their potential for chemical bond formation had reached the maximum and the adhesive force 
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could not increase. The values of A increased with increase of the polymer concentration thanks 
to the physical mechanisms between the polymer and the mucin. These results correspond with 
the phenomena described by Park and Munday. There was no significant difference between the 
values of F and A in the cases of CLNaHA and NaHA. ZnHA does not have a gel-like structure 
at 0.5% w/w which would enable it to interpenetrate and form entanglements in the same way as 
for the other two derivatives. At higher ZnHA concentrations, F and A increased because of the 
gel-like structure, but not so strongly as for the other two derivatives.  
The tensile test results correlated with the results of the rheological measurements. In both 
cases, CLNaHA and NaHA showed the highest capability for mucoadhesive bond formation, and 
ZnHA the lowest.  
Ex vivo measurements were also performed. Gels were placed in contact with excised porcine 
conjunctiva (Fig. 11). These measurements related to conditions closer to the real mucoadhesive 
circumstances of the eye.  
 
 
Fig. 11. Work of adhesion of ( ) CLNaHA, ( ) NaHA and ( ) ZnHA as a function of the 
concentration of the polymer in contact with excised porcine conjunctiva (***: p ≤ 0.001, highly 
significant compared with CLNaHA) 
 
The values of A were at least twice as high in the ex vivo measurements as those measured 
with mucin in the case of the in vitro measurements. This is beneficial for ophthalmic therapy, 
because it can be predicted that the mucoadhesion of the gels will be higher on the surface of the 
eye. In these measurements, CLNaHA gave significantly higher A values than those of the other 
two derivatives. Its nanosized structure leads to easier and deeper interpenetration and more 
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facile chemical bond formation with the mucus layer of the eye. The pronounced mucoadhesive 
behaviour of CLNaHA at 0.5% w/w was also seen in the ex vivo measurements, proving the 
possibility of prolonging the residence time on the eye surface even at low CLNaHA 
concentration. NaHA and ZnHA under ex vivo circumstances were probably not able to 
interpenetrate to the same extent as CLNaHA, but they showed an increase in mucoadhesion and 
no significant difference was observed between them.  
 
4.1.4. Drug release 
The drug release from CLNaHA, NaHA and ZnHA at 1% w/w polymer concentration 
containing 0.1% w/w SD was measured with a vertical Franz diffusion cell. Figure 12 shows the 
amount of drug released (% w/w) during the examination time (h). The slopes were determined 
(Eq. 9; section 3.2.7.1) by power law fitting to the curve of the released drug amount (% w/w) 
versus time (h) of CLNaHA, NaHA and ZnHA.  
 
 
Fig. 12. Release of SD from ( ) CLNaHA, ( ) NaHA and ( ) ZnHA  
 
In the first hour of measurements, a rapid diffusion of SD was observed from all three 
formulations, but their release profiles then diverged. There was no significant difference 
between CLNaHA and NaHA in the first hour, but CLNaHA later released a higher amount of 
SD as compared with NaHA. This can be explained by the easier diffusion of SD from the 
CLNaHA gels, due to the smaller particle size and lower viscosity. NaHA has a linear structure 
and SD probably cannot diffuse to such an extent as in the case of CLNaHA. ZnHA released a 
significantly lower amount of SD, even in the first hour, possibly because interactions may occur 
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between SD and ZnHA. This needs to be investigated, but did not constitute part of the present 
research work.  
The slopes in the first hour indicated non-Fickian drug release in the cases of CLNaHA 
(n = 0.6081, R
2 
= 0.9996) and NaHA (n = 0.5814, R
2 
= 0.9997), because the n values were 
between 0.5 and 1. In these anomalous processes of drug release, both diffusion through the 
hydrated layers of the matrix and polymer chain relaxation/erosion are involved. The Fickian 
contribution to the overall release process decreases with increasing amount of drug released. 
Thus, the relaxation of the polymer chains becomes more pronounced, which is expected since 
water is taken up simultaneously with drug release, and this water leads to polymer chain 
relaxation (Peppas and Buri, 1985; Ritger and Peppas, 1987; Peppas et al., 2000; Park and 
Munday, 2002; Baumgartner et al., 2006). In the case of ZnHA (n = 1.0013, R
2 
= 0.9988), zero-
order kinetics was observed in the first few hours of diffusion, which confirms the possibility of 
interactions between SD and ZnHA.  
In conclusion, it can be established that all the derivatives undergo rapid release, and release 
more than 65% w/w of the SD up to 6h. This release profile is beneficial in ocular therapy, 
because the therapeutic dosage can be reached at the beginning of the application, which is 
followed by a sustaining dosage.  
 
4.1.5. Conclusion 
The investigated CLNaHA and NaHA are biocompatibile, while ZnHA displayed lower 
biocompatibility. CLNaHA showed the highest capability for mucoadhesion, due to its 
nanoparticulate structure, which can easily interpenetrate and form secondary bonds with mucin. 
The structure of ZnHA hampers interpenetration, entanglement and bond formation, which 
results in lower adhesive force and work of adhesion values. From all three derivatives, rapid SD 
release was observed in the initial period, which is especially beneficial in ocular therapy.  
Although ZnHA has weaker mucoadhesive, drug release properties and lower 
biocompatibility in vitro, its application in ophthalmic formulations is favourable due to its 
scavenging, bactericidal, bacteriostatic and fungicidal effects, which allows omission of the 
preservative from the formulation. However, the nanosized CLNaHA with its increased 
mucoadhesion, even at lower concentrations, is preferable for use in ophthalmic preparations so 
as to increase the residence time of the active agent.  
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4.2. Second generation mucoadhesive polymers 
4.2.1. Preformulation measurements 
An ideal ocular dosage form is able to integrate easily into the environment of the eye or into 
its tissues; in the case of a surface−administered formulation (e.g. eye drops), this can mean the 
tear film. For this reason, the physiological properties of the tear film must be taken into 
consideration (Table 1).  
In the event of an ocular drug delivery formulation, the needs of the patients’ must be 
respected. Side-effects influencing vision can reduce their willingness to take their medication. 
Thus, ocular drug delivery systems must not cause a feeling of sand in the eyes, dry eye or blurry 
vision (Taylor et al., 2002; Lafuma et al., 2011). 
 
Table 1. Physiological properties of the tear film 
 Values Literature 
pH 7.4 Ludwig 2005 
Osmolality 310-350 mOsm kg
-1
 Ludwig 2005 
Surface tension 44 mN m
-1
 Ludwig 2005 
Refractive index male: 1.3368; female: 1.3371 Patel et al., 2000 
 
During ocular drug delivery formulation, various excipients are used which can change the 
physical and chemical properties of the ocular surface and the stability of the tear film (Yañez-
Soto et al., 2014).  
In a hyperosmotic tear environment, water flows out of the cells to balance the osmolality of 
the intracellular fluids and the surrounding tears, resulting in dehydration of the cells in the 
ocular surface and damaging the cell membranes. Hypoosmolality is well tolerated by patients, 
but if it is very low it can cause irritation of the eye.  
Eye drops of pH 6-9 do not cause discomfort, but outside this range an increased production 
of tear fluid can be observed due to the irritation (Ziemssen and Zierhut, 2008; Januleviciene et 
al., 2012).  
I determined the osmolality, surface tension and refractive index of polymer solutions at five 
concentrations (Table 2).  
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Table 2. Measured values of osmolality, surface tension and refractive index of polymer 
solutions 
Concentration 
(% w/w) 
Osmolality  
(mOsm/l) 
Surface tension  
(mN/m) 
Refractive 
index 
 mean ± SD mean ± SD  
1 4.3 ± 0.5 75.3 ± 0.3 1.3330 
3 8.0 ± 0.0 75.4 ± 0.3 1.3330 
5 11.0 ± 1.6 75.3 ± 0.2 1.3332 
7 17.0 ± 2.2 75.4 ± 0.1 1.3339 
10 19.3 ± 0.5 75.4 ± 0.2 1.3342 
 
The results revealed that the polymer has a very low osmotic activity. Increase of the polymer 
concentration resulted in an increase in osmolality, but this was not of great significance. These 
values are beneficial: after the osmolality of the eye drops has been set with an isotonizing agent, 
the ThioPASP will not result in a hyperosmotic solution.  
The measured surface tension and refractive index values differ slightly from those of water 
(71.99 ± 0.05 mN m
-1
 and 1.3330, respectively) (Pallas and Harrison, 1990). Increase of the 
polymer concentration did not influence the surface tension, but the refractive index increased to 
a small extent. Thus, ThioPASP solutions do not lower the surface tension of the tears, leading to 
irritation, and do not cause visual interference.  
The pH of the ThioPASP solution prepared with distilled water or with PBS was 5.4 and 7.4, 
respectively. For eye drop formulation, therefore, ThioPASP solution should be prepared in 
buffer so as to meet the pH requirements necessary to avoid irritation.  
The transmittance spectrum of ThioPASP was measured in order to characterize the possible 
effects of the solution on the vision (Fig. 13).  
Such spectral transmittance curves reveal that ThioPASP solutions are transparent in visible 
light, which means that they will not cause any visual disturbance. Increase of the polymer 
concentration resulted in a shift of the curves towards longer wavelengths, but even at the highest 
concentration the polymer solution does not have many effects on vision.  
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Fig. 13. Spectral transmittance curves of ThioPASP solution at five concentrations  
 
The osmolality, surface tension, refractive index, transmittance and pH measurement results 
indicate that ThioPASP may be a very promising eye drop formulation. Thanks to its inert 
properties, ThioPASP solution does not affect the tear stability, and the ophthalmic requirements 
can be achieved through the addition of necessary excipients such as the isotonizing and surface 
tension−modifying agents.  
 
4.2.2. Cytotoxicity  
Cytotoxicity measurements were performed with the MTT assay on the RCE cell line. Only 
the viable cells are able to reduce the dye MTT to formazan. Figure 14 shows the viability of 
cells after contact with ThioPASP solution samples relative to control cells.  
 
 
Fig. 14. Cell viability after contact with ThioPASP solutions 
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The results demonstrate that ThioPASP solution is biocompatible, because the cell viability 
was >90% after a contact time of 3 h in all cases. This is an extremely important finding, 
especially because RCE cells are very sensitive, so that it can be predicted that ThioPASP 
solution will highly probably not have a toxic effect on the eye.  
 
4.2.3. Gel formation  
The gelation process and the gel structure were characterized by means of rheology. The 
effects of the polymer concentration (7 or 10% w/w) were studied (Fig. 15).  
 
 
Fig. 15. Effects of polymer concentrations on the storage modulus (G’) of ThioPASP as a 
function of the gelation time; the polymer concentrations are ( ) 7% w/w and ( ) 10% w/w  
 
Gelation did not proceed at polymer concentrations lower than 10% w/w. At high polymer 
concentration (10% w/w) after the addition of oxidant, cross-links were formed, resulting in the 
gelation of ThioPASP.  
The frequency sweep test was started after full gelation. Table 3 presents G’ and G’’ values of 
the formulations at an angular frequency of 1 s
-1
.  
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Table 3. Storage (G’) and loss moduli (G’’) of ThioPASP systems at different polymer 
concentrations (ω = 1 s-1) 
ThioPASP conc. 
(% w/w) 
G’ G’’ 
3 0.18 0.02 
5 0.11 0.02 
7 16.28 1.35 
10 533.0 12.6 
 
At polymer concentrations lower than 7% w/w, changes of the polymer concentration did not 
affect the gelation, G’ did not vary significantly and the precursor solutions remained in the 
liquid state even after the addition of oxidant (G’ was similar in order of magnitude to G’’). At 
polymer concentration of 7% w/w, a gel structure formed (G’ was more than an order of 
magnitude higher than G’’). At high polymer concentrations (7 and 10% w/w), the values of G’ 
increased with increase of the polymer concentration. The gel obtained at 10% w/w ThioPASP 
displayed the strongest gel structure, indicating that the elevation of the polymer concentration 
enhanced the cross-linking density by increasing the concentration of disulfide linkages.  
 
4.2.4. Swelling of ThioPASP hydrogels 
The swelling of the hydrogels was characterized by a gravimetric method. Formulations of 
20% w/w ThioPASP gels were measured. During the 6 h measurements, the swollen polymer 
discs maintained their coherent structure and shape, because of the formation of disulfide 
linkages between the polymer chains.  
Figure 16 depicts the percentage swelling (% S), calculated from Eq. 6 section 3.2.4.1.  
32 
 
 
Fig. 16. Swelling kinetics of ThioPASP hydrogels 
 
The polymer swelled faster initially and the water uptake then slowed as equilibrium was 
approached. The swelling ability of the hydrogel was large because of the lower cross-linking 
density resulting from the weaker elastic interactions inside the polymer network. This led to a 
marked water uptake of the formulation. ThioPASP was able to swell to 6000-7000% of the 
volume of its dry mass. The swelling exponent (n) was calculated via Eq. 7 (section 3.2.4.1) and 
curve fitting. In our case, non-Fickian diffusion was observed, because the n value was 0.874 
(Karadağ et al., 2002).  
The results of water uptake measurements indicated that the ThioPASP polymers have a very 
good water uptake capacity, which plays an important role in mucoadhesion and also in drug 
release.  
 
4.2.5. Mucoadhesion 
4.2.5.1. Rheology 
Rheological measurements were performed with different concentrations of ThioPASP 
polymer and mucin. It was presumed that, if an in situ gelling system is used, the mucin can 
influence the gelation time of the formulation. For this reason, the gelation time was first 
determined in the presence of mucin, using the same method as described before. The results are 
shown in Fig. 17.  
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Fig. 17. Evolution of storage modulus (G’) as a function of time at ( ) 7% w/w and ( ) 
10% w/w polymer concentrations with (solid symbols) or without (open symbols) mucin 
 
As in the previous measurements without mucin, gelation was observed only at 7 and 
10% w/w ThioPASP. Mucin did not cause an appreciable difference in the rheological 
parameters at ThioPASP concentrations lower than 7% w/w. The gelation time was also defined 
as the time at which a maximum was observed in the curve of the differential with respect to 
time (Table 4) (Ma et al., 2008).  
 
Table 4. Gelation time (tg) at 7 and 10% w/w ThioPASP concentrations 
ThioPASP conc. tg without mucin  tg with mucin 
(% w/w)  (s)  (s) 
3 n. g. n. g. 
5 n. g. n. g. 
7 n. g. 450 
10 330 300 
n. g. – no gelation was observed 
 
In the cases of 7 or 10% w/w polymer, the gelation time was shorter. The addition of mucin 
aided the gelation and in each case the gelation time was shorter in the presence of mucin. The 
rate of gelation and the final value of G’ were higher in the presence of mucin.  
Frequency sweep tests were performed after gelation to investigate the interaction between 
the mucin and the ThioPASP gels. Figure 18 presents the variation in G’ with angular frequency 
for the formulations with and without mucin. 
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Fig. 18. Frequency sweep tests at (a) 3, (b) 5, (c) 7 and (d) 10% w/w polymer concentrations 
with (solid symbols) or without mucin (open symbols) 
 
In all cases, mucin augmented the elastic modulus of the samples, indicating that interactions 
occurred between the polymer and the mucin. The shapes of the curves (the slopes of the G’ vs. 
angular frequency curves, which show the frequency dependency of the systems) of the samples 
with 10% w/w polymer with or without mucin were similar to each other. At this concentration, 
the polymer gels exhibited a densely cross-linked gel structure even without mucin. Mucin did 
not change the rheological profile of the systems. The changes in the rheological behaviour of 
the samples containing lower polymer concentration (3 and 5% w/w) suggested the formation of 
a chemically cross-linked structure between the polymer and mucin chains in addition to 
physical entanglements. In a physically entangled structure, the moduli depend strongly on the 
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frequency: at low frequency, the G’ values are decreased considerably (Ross-Murphy and 
McEvoy, 1986; Madsen et al., 1998). In our case, at lower ThioPASP concentrations, the added 
mucin decreased the slope of the curves, which indicated the occurrence of the cross-linking of 
the polymer with the mucin. 
Table 5 shows the relative synergism parameters (Eqs. 4 and 5; section 3.2.3.1) η* and G’ at 
an angular frequency of 1 s
-1
.  
 
Table 5. Relative synergism parameters of viscosity and storage modulus between the 
polymer−mucin mixtures 
ThioPASP conc. 
(% w/w) 
∆𝐺𝑟𝑒𝑙
′  𝛥𝜂𝑟𝑒𝑙
∗  
3 31.85 36.11 
5 5.28 7.78 
7 2.44 2.44 
10 2.31 2.31 
 
The stiffness of the gels was larger in the presence of mucin in each case. At higher polymer 
concentrations, the relative differences (∆𝐺𝑟𝑒𝑙
′  and 𝛥𝜂𝑟𝑒𝑙
∗ ) were lower than at lower polymer 
concentrations. The mucoadhesive character was displayed most significantly at lower polymer 
concentrations (3 and 5% w/w). This result is in accordance with earlier studies in which it was 
concluded that there is an optimum polymer concentration for mucoadhesion (Madsen et al., 
1998). In our work, this was probably because a loosely, chemically cross-linked structure was 
present, and the chains were flexible enough to be able to form more bonds with the mucin, 
resulting in a gel-strengthening effect in the mixture.  
 
4.2.5.2. Tensile tests 
Tensile test measurements were also made with 3, 5, 7 and 10% w/w polymer in vitro with 
mucin dispersion (Fig. 19).  
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Fig. 19. ( ) Adhesive force (F) and ( ) work of adhesion (A) as functions of polymer 
concentration  
 
Figure 19 reveals that A increased continuously as the concentration was elevated, while the 
adhesive force (F, mN) reached a maximum at 7% w/w polymer. As indicated earlier (Park and 
Munday, 2002), in our work the chemical bonds probably have a larger effect at lower polymer 
concentration, and it is likely that covalent bonds and secondary bonds were formed with the 
mucin glycoproteins. Thus, F increased continuously with increasing polymer concentration. At 
high polymer concentration, the potential for chemical bonds reached a maximum because the 
free thiol groups were saturated at the interface. Accordingly, a plateau was observed in the F vs. 
concentration curve. A did not reach a maximum, but increased continuously, because 
interpenetration prevails in the process of mucoadhesion rather than chemical bonding at higher 
polymer concentrations. In our case, the ThioPASP gel at higher concentration has more thiol 
groups and more cross-links, resulting in a gel structure, which induces increased swelling, 
allowing deeper and improved interpenetration. 
These tensile test results can be correlated to the rheological results, where the changes in the 
shape of the frequency sweep curves could be observed up to 7% w/w polymer concentration, 
which indicated the formation of chemical cross-links (Hägerström and Edsman, 2003). 
Tensile test measurements were also performed ex vivo on excised porcine conjunctiva (Fig. 
20.).  
37 
 
 
Fig. 20. Work of adhesion (A) as a function of polymer concentration in ex vivo measurements 
 
In ex vivo tensile test measurements, A increased continuously as the polymer concentration 
was elevated up to 7% w/w. At high concentration (10% w/w), the ThioPASP polymer is not 
able to interpenetrate into the mucous layer of the porcine conjunctiva, probably because a 
highly cross−linked structure, which is less flexible is formed at this concentration.  
We can conclude that ThioPASP concentration has a high effect on mucoadhesion. At high 
polymer concentration, the interpenetration into the mucous layer is limited. These results 
correspond with the calculated rheological relative synergism parameters, where it was also 
found, that the mucoadhesiveness of ThioPASP polymers decreases at 10% w/w polymer 
concentration.  
 
4.2.5.3. ‘Wash away’ measurements  
‘Wash away’ ex vivo measurements mimic the lacrimation of the eye, under conditions 
relatively close to real mucoadhesive circumstances of the eye. The amount of sodium 
fluorescein washed away from the porcine conjunctiva can indicate the amount of the dosage 
form remaining on the surface. In our work, HEC gels were used as reference.  
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Fig. 21. (a) ThioPASP and (b) HEC containing the model drug. Polymer concentrations: ( ) 
5% w/w, ( ) 7% w/w and ( ) 10% w/w 
 
It can be observed in Fig. 21a that increase of the ThioPASP concentration was accompanied 
by a slight decrease in the amount of model drug washed away. These differences were not 
pronounced after 1 h. In the case of the reference systems (HEC gels, Fig. 21b), the observations 
were similar; the gel with the lowest HEC concentration underwent the fastest washing−out. 
Comparison of the ThioPASP systems with the HEC gels indicated that the ThioPASP 
formulations have a longer residence time, because 40% w/w of the model drug remained on the 
conjunctiva, in contrast with 10-30% w/w for the reference systems.  
 
4.2.6. Effects of blinking on the gel structure 
During the formulation of a mucoadhesive ocular drug delivery system, eye movements and 
blinking must be taken into consideration, because the gel on the surface of the eye is exposed to 
a continuous shear force, which may thin or dislodge the formulation (Robinson and Mlynek, 
1995). As a result, the gel structure may be disrupted under this shear. The strength of the gel 
was investigated in cycling strain tests, simulating the real circumstances in the eye. One 
blinking cycle can correspond to 1 min of blinking (Fig. 22).  
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Fig. 22. Modification of gel structure at 10% w/w ThioPASP during blinking cycles: storage 
modulus ( ) and loss modulus ( ) with (filled symbols) or without (empty symbols) mucin  
 
Figure 22 depicts the changes in the structure during the blinking cycles. It can be observed 
that the moduli decreased only in the first two cycles and later became practically constant. The 
form applied to the eye surface remained in a gel state during blinking, as indicated by the 
constant phase moduli. The large G’ value and the difference between the moduli indicated the 
presence of the gel structure, which preserved its strength after several test cycles. There was no 
difference between the shapes of the curves in the cases of mucin-containing and mucin-free 
samples. The only difference was in the value of the storage modulus; the mucin-containing 
sample gave higher values, the mucoadhesivity being maintained under shear. 
 
4.2.7. Drug release measurements 
Drug release measurements were performed with a vertical Franz diffusion cell system with 
gels containing 10% w/w polymer and 0.1% w/w SD. Figure 23 shows the amount of drug 
released (% w/w) during time.  
In the first hour, the diffusion of the SD was fast, and this was followed by a sustained 
release. The drug release results correspond with the swelling measurement results. The 
formulation has a higher water uptake, suggesting a lower cross-linking density, and the SD is 
therefore able to diffuse through this structure more easily.  
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Fig. 23. Release of the model drug, SD, from ThioPASP gel 
 
The swelling-controlled drug release mechanism can be characterized by Eq. 9 (section 
3.2.7.1) where the n value can be determined from the equation of the power law fitted to the 
curve of the amount of drug released (% w/w) against time (min).  
In our case, we have a non-Fickian release mechanism, because the value of n is 0.6561, 
which corresponds with our swelling results. During the drug release, our 10% w/w polymer gels 
underwent continuous swelling on the membrane, which led to the simultaneous absorption of 
water and desorption of the drug via a swelling-controlled diffusion mechanism. The 
combination of diffusion, swelling and relaxation is responsible for the non-Fickian release 
mechanism (Lee, 1985; Peppas and Buri, 1985; Ritger and Peppas, 1987; Peppas et al., 2000; 
Park and Munday, 2002; Baumgartner et al., 2006). 
The advantage of these formulations is the rapid drug release in the first hour, followed by a 
prolonged release. This is important in therapy, because a higher dose is needed immediately 
after the application, in order to reach the therapeutic dosage, after which a sustaining dosage is 
required. From the aspect of ophthalmic preparations, this can increase patient compliance.  
 
4.2.8. Effect of the stabilizing agent on the ThioPASP properties 
I determined the effects of the stabilizing agent on the polymer structure and properties such 
as their mucoadhesion and drug release. Dithiothreitol (DTT), glutathione (GSH) and 
acetylcysteine (ACC) stabilized ThioPASP polymers were characterized.  
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4.2.8.1. Mucoadhesion measurements 
To determine the effects of the stabilizing agents on the mucoadhesivity of the systems, 
rheological and tensile test measurements can be used with the calculation of synergism 
parameters in the case of rheology and normalized mucoadhesion parameters from the tensile 
test.  
Figure 24 shows the calculated absolute (Eq. 2; section 3.2.3.1) and relative (Eq. 4; section 
3.2.3.1) synergism parameters of G’ at an angular frequency of 1 s-1, the calculated normalized 
mucoadhesion parameters (Eq. 8; section 3.2.5.1) in the case of the tensile tests.  
 
  
 
Fig. 24. The calculated a) absolute and b) relative synergism parameters of G’ in rheological 
measurements and the calculated c) normalized mucoadhesion parameters in tensile tests 
 
Dithiothreitol stabilized formulations (DTT) did not show mucoadhesion in the bulk 
rheological method; moreover, increase of the polymer concentration reduced the gel structure, 
resulting in increasingly more negative ΔG’ and very low ΔG’rel values. However in the case of 
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tensile tests as a surface method, mucoadhesion was observed, which decreased as the 
concentration was elevated. These calculations predict that dithiotreitol as stabilizing agent 
prefers polymer−polymer interactions, but even in this case it can provide a limited 
mucoadhesion on the interface.  
The GSH as a glutathione stabilized sample at low polymer concentration was mucoadhesive 
in the bulk method, but with increase of the polymer concentration its mucoadhesivity decreased. 
As compared with the dithiothreitol stabilized samples, the tensile tests indicated a weak 
mucoadhesive property, which can be explained by its weak cohesivity (the gels fell apart during 
the experiments) and resistance against the tensile strength.  
Up to 7% w/w polymer concentration, the acetylcysteine stabilized formulation (ACC) 
showed marked mucoadhesivity relative to the other two formulation types. At 7% w/w, a gel 
structure was formed which can provide optimum mucoadhesion, as proved by both bulk and 
tensile test methods (high values of ΔG’, ΔG’rel and ΔAUC/AUC).  
 
4.2.8.2. Drug release 
The SD release from the DTT, GSH and ACC gels (at the optimum, 7% w/w polymer 
concentration) was determined with the vertical Franz diffusion cell system during 24 h (Fig. 
25).  
 
Fig. 25. Release of SD from ThioPASP gels: ( ) DTT; ( ) GSH and ( ) ACC 
 
The results revealed that the GSH gels released the highest amount of SD (~80% w/w) during 
24 h, while there was no significant difference between the lower amounts of SD released by 
DTT and ACC.  
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Table 6 shows the n values determined from the equation of the power law fitted to the curve 
of the amount of drug released (% w/w) against time (min) according to Eq. 9 (section 3.2.7.1).  
 
Table 6. Release exponents (n) of DTT, GSH and ACC 
 n R
2
 
DTT 0.6781 0.9914 
GSH 0.5542 0.997 
ACC 0.6674 0.9948 
 
The fitting results demonstrate that all samples display non-Fickian diffusion, because the n 
values are between 0.5 and 1. The non-Fickian release mechanism is a swelling−controlled 
mechanism, with simultaneous water uptake and API desorption (Peppas and Buri, 1985; Ritger 
and Peppas, 1987; Peppas et al., 2000; Park and Munday, 2002; Baumgartner et al., 2006).  
It can be concluded that GSH has the fastest release thanks to the disrupted structure, which 
cannot be predicted and planned in advance. Even if DTT and ACC release lower amounts of SD, 
their release profile can be designed thanks to their stable structure. The in vitro results indicate 
that the formulations can provide 24 h continuous release.  
 
4.2.9. Conclusion 
The ThioPASP polymer is a new type of mucoadhesive polymer that is planned to be used in 
ophthalmic therapy. Since such polymers had not been used previously, preformulation 
measurements were first performed in order to verify the suitability of these polymers for 
ophthalmic formulations. The results demonstrated that ThioPASP solutions are biocompatible 
and will not cause blurred vision. 
In situ gellable ThioPASP hydrogels were fabricated with the aim of obtaining delivery 
vehicles with increased adhesion to the eye surface, and the next important step was therefore to 
characterize these hydrogels in terms of gelation time, viscoelastic behaviour, mucoadhesion, 
resistance against blinking and lacrimation and drug release. Mucin exhibited a strong effect on 
cross-link formation, and the ThioPASP gels displayed strong mucoadhesion, especially at lower 
polymer concentrations (3 and 5% w/w). The formation of disulfide linkages with mucin 
glycoproteins contributed to the strong mucoadhesion, in addition to chain entanglement during 
the interpenetration of the polymer into the mucin. The addition of a small amount of oxidant 
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improved the mucoadhesion, because of the formation of a gel structure with a considerable 
number of free thiol groups.  
The ThioPASP gels demonstrated high resistance against lacrimation of the eye, which 
confirmed the strong mucoadhesion. These polymers are also resistant against blinking. SD 
could be encapsulated into the ThioPASP polymers during formation of the gel structure and 
underwent rapid release in the first hour during in vitro measurements, followed by sustained 
release of the drug for a further 23 h.  
The next important step was the stabilization of ThioPASP polymers, where three types of 
reducing agents were used (DTT, GSH and ACC). The aim was to find an optimum stabilizing 
agent which can ensure an appropriate gel structure for mucoadhesion and drug release. The 
results revealed that ThioPASP stabilized with acetylcysteine has an optimum cross−linked 
structure with free thiol groups ensuring polymer−mucin interactions, resulting in the best 
mucoadhesive properties.  
 
5. SUMMARY 
The aim of my research work was to characterize hyaluronic acid (HA) derivatives as first 
generation and thiolated poly(aspartic acid) (ThioPASP) polymers as second generation 
mucoadhesive polymers as potential ocular drug delivery system vehicles. The generally poor 
bioavailability of ophthalmic formulations can be improved by new formulations with a 
prolonged residence time.  
Comparative studies of HA derivatives from the aspects of mucoadhesion and drug release 
have not been reported previously. Likewise, a cross−linked sodium salt of HA (CLNaHA) has 
not been used before as a potential ocular drug delivery system vehicle.  
ThioPASP polymers as a new type of mucoadhesive polymers were studied first in a wide 
range from the aspects of ophthalmic preformulation (osmolality, surface tension, refractive 
index, transmittance and cytotoxicity) and formulation (hydrogel characterization, mucoadhesion 
and drug release).  
The results of the measurements with the HA derivatives and the ThioPASP polymers led to 
the following conclusions:  
 Both the HA derivatives and the ThioPASP polymers are biocompatible, as proved by the 
MTT test on RCE cell line.  
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 Their good mucoadhesive property was verified in vitro (rheological and tensile tests) and 
ex vivo (tensile tests). In the ex vivo tensile tests, higher values of adhesive work were 
measured, predicting a better in vivo mucoadhesion. Thanks to this property, the residence 
time on the eye can be prolonged.  
 Both HA derivatives and ThioPASP polymers exhibit a fast initial release of sodium 
diclofenac, followed by a sustained release up to 24 h. This is beneficial in ophthalmic 
therapy because the therapeutic effect can be achieved at the beginning of the application, 
which is followed by a sustaining dosage.  
 The use of HA derivatives gives an opportunity to find the optimum salt and structure for 
the required therapy.  
 Although ZnHA displayed lower biocompatibility and mucoadhesion, its bactericidal and 
fungicidal properties can give an opportunity to decrease or eliminate the amount of 
preservatives from the formulation (such preservatives can cause cellular damage during 
long−term ophthalmic therapy).  
 Of the HA derivatives tested, CLNaHA had the optimum structure for mucoadhesion and 
drug release. These results justify the use of CLNaHA in ophthalmic therapy in the future.  
 In situ gelling can be achieved through the use of ThioPASP polymers. This property is 
very beneficial in ocular therapy because such polymers can be used as eye drops and will 
gellify in situ.  
 ThioPASP polymers are inert excipients, which simplifies the formulation of ocular drug 
delivery system.  
 ThioPASP polymers are also resistant against lacrimation and blinking, as proved by the 
“wash away” and rheological tests. These properties also play an important role in 
prolongation of the residence time on the ocular surface.  
 The ThioPASP polymer stabilized with acetylcysteine exhibited the best mucoadhesive 
and drug release properties.  
All of the results of the measurements performed excellently illustrated the potential of the 
application of the HA derivatives and the ThioPASP polymer as mucoadhesive ocular drug 
delivery system vehicles, with the beneficial property of reducing the necessary frequency of 
use.  
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Sodium diclofenacThe ophthalmic formulations on the market suffer from poor bioavailability, and it would therefore be
useful to design a new formulation which is able to prolong the residence time and reduce the adminis-
tration frequency. Polymer matrices which exhibit strong mucoadhesion are promising platforms in ocu-
lar drug delivery from the aspect of improved bioavailability. In the present study, an in situ gelling,
mucoadhesive drug delivery system was fabricated from thiolated poly(aspartic acid) (ThioPASP). The
thiol groups of ThioPASP are able to form disulphide linkages with the mucin glycoproteins and prolong
the residence time on the eye. The effects of the thiol groups on the structure, swelling behaviour and
mucoadhesive character of the gel and on the drug release proﬁle were determined. The gel structure
was characterized by means of rheology. The ThioPASP gel was demonstrated by rheology, tensile test
and ‘wash away’ measurements to display strong mucoadhesion. The drug release from the ThioPASP
gel was studied on a vertical Franz diffusion cell: a burst release of sodium diclofenac occurred in the ﬁrst
hour, followed by sustained release of the encapsulated drug for up to 24 h. The results proved the impor-
tance of the presence of the thiol groups and suggested that a ThioPASP formulation can be useful as an in
situ gelling, ocular dosage form.
 2014 Elsevier B.V. All rights reserved.1. Introduction
The formulation of ocular drug delivery systems poses many
challenges, but also offers many opportunities to overcome the
inadequacies of the current formulations. In consequence of the
limited area and time for absorption in the eye, the bioavailability
of ocular drugs is very poor (less than 5%). The corneal epithelium
has a complex hydro- and lipophilic character that limits drug
absorption and the eye has many protective mechanisms, includ-
ing blinking, the tear turnover and reﬂex lachrymation. The con-
junctiva is the major site of systemic absorption which also plays
an important role in drug elimination from the ocular surface
thanks to its rich blood ﬂow, large surface area and more perme-
able membrane compared to the corneal membrane. There istherefore a need for the frequent instillation of eye drops, which
is accompanied by discomfort and a decrease in patient compli-
ance, especially in long-term therapy (Urtti et al., 1990; Urtti and
Salminen, 1993; Ludwig, 2005; Junginger et al., 2002; Pepic´ et al.,
2013).
One of the most important phenomena in ocular formulations is
the adhesion between the drug delivery system and the eye tissues.
In the case of bioadhesion, physical or chemical bonds are
formed between the biological and synthetic surfaces. Mucoadhe-
sive drug delivery vehicles exploit the adhesion between the poly-
mer component and the biological tissue, a mucosal membrane,
the mechanism being referred to as mucoadhesion (Chickering
and Mathiowitz, 1999). In case of ocular mucus, the conjunctival
goblet cells, the conjunctival epithelium, and the corneal epithe-
lium are responsible for the secretion of mucin. Mucins are large
glycoproteins which are mainly composed of a protein core, carbo-
hydrates and are well glycosylated. There are two types of ocular
mucins: membrane-associated and secreted mucins (Lorentz and
Sheardown, 2014).
2 G. Horvát et al. / European Journal of Pharmaceutical Sciences 67 (2015) 1–11Mucoadhesion can be described in three steps: (1) the forma-
tion of an intimate contact between the mucoadhesive preparation
and the mucus, followed by the wetting of the mucoadhesive for-
mulation; (2) the swelling of the macromolecules and the forma-
tion of an interpenetrating network with the mucus
macromolecules; and (3) chemical bond formation (primary or
secondary) between the entangled chains (Duchêne et al., 1988).
Thus physical and chemical interactions can arise during the pro-
cess of mucoadhesion.
Numerous theories have been put forward to explain the com-
plex phenomenon of mucoadhesion, such as electronic, adsorption,
wetting, diffusion and fracture theories. It is difﬁcult to compare
these theories, but they may well supplement each other and
reﬂect the complex nature. The electronic theory is based on the
different electronic structures of the polymer and mucin; it follows
that a double layer of electrical charge is formed on the interface.
The adsorption theory is based on the formation of van der Waals
interactions, hydrogen-bonds, etc. The wetting theory relates to
the ability of the mucoadhesive polymer to spread over a tissue.
The most important step in the diffusion theory is the interpene-
tration of the polymer chains in the mucus. The fracture theory
analyses the forces required to separate the two surfaces after
adhesion (Chickering and Mathiowitz, 1999; Serra et al., 2009).
Numerous experimental methods have been described for the
measurement of mucoadhesion. Most are based on two
approaches: (1) surface analysis, such as contact angle determina-
tion and spectroscopic techniques, and (2) determination of the
bioadhesive bond strength in tensile or rheological tests (Peppas
and Buri, 1985).
The new delivery systems with mucoadhesive properties have
various advantages: better bioavailability, a lower active ingredi-
ent concentration is sufﬁcient and the administration frequency
can be decreased, thanks to the enhanced residence time
(Andrews et al., 2009; Saettone et al., 1985). The strength of
mucoadhesion is determined by the polymer: its molecular mass,
the presence of functional groups, the chain ﬂexibility, the concen-
tration, the degree of cross-linking and the degree of hydration
(Andrews et al., 2009; Leitner et al., 2003; Ludwig, 2005; Leung
and Robinson, 1990; Robinson and Mlynek, 1995).
The mucoadhesive polymers can be classiﬁed into two main
categories. The ﬁrst-generation mucoadhesive polymers can be
anionic (e.g. poly(acrylic acid), sodium carboxymethylcellulose),
cationic (e.g. chitosan) or non-ionic. The second-generation
mucoadhesives are derivatives of the ﬁrst-generation polymers
(e.g. thiolated polymers) and include several new mucoadhesives
(e.g. lectins, bacterial adhesions) (Andrews et al., 2009; Serra
et al., 2009).
Thiolated polymers (thiomers) are mucoadhesive polymers
with thiol group-containing side-chains (Bernkop-Schnürch,
2005). The most commonly used thiomers are synthetized from
chitosan, alginate, polyacrylates and cellulose derivatives
(Andrews et al., 2009). In contrast with the ﬁrst-generation poly-
mers, they are capable of forming covalent (disulphide) bonds with
cysteine-rich subdomains of the mucus layer (Bernkop-Schnürch,
2005). Other advantages of thiomers include permeation enhance-
ment through the reversible opening of the tight junction, enzyme
inhibition and efﬂux pump inhibition (Gradauer et al., 2013; Iqbal
et al., 2011; Rahmat et al., 2012). As a result of these advantages
these polymers ensure the prolongation of the residence time
and increase the bioavailability, and they can be used in many
medical ﬁelds (e.g. topical ocular therapy) in various dosage forms,
such as liquid drops, gels or mini-tablets.
In our work, thiol-containing side-groups were bonded to
poly(aspartic acid) (PASP). PASP is a biocompatible and biodegrad-
able polymer by virtue of its protein-like structure, and its degra-
dation products are excreted by the physiological mechanisms ofthe body. It is not toxic and does not generate immunogenicity.
PASP is currently used as a material component in dialysis mem-
branes, artiﬁcial skin, drug delivery systems and orthopaedic
implants in biomedical applications (Gyarmati et al., 2013;
Gyenes et al., 2008; Roweton et al., 1997; Zrínyi et al., 2013).
The goal of our work was to develop a mucoadhesive formula-
tion from thiolated PASP (ThioPASP) polymers which could be used
as an in situ gelling, ophthalmic drug delivery system by spreading
it on the surface of the eye or instilling it into the cul-de-sac. An
important step was to ﬁnd the ideal oxidized state of the polymers.
The gel structure formed was characterized by rheology. The func-
tions of the thiol groups (their effects on the gel structure and on
the mechanism and strength of mucoadhesion) were determined.
Rheology, tensile tests and ‘wash away’ measurements were per-
formed to characterize the mucoadhesion. Since the ThioPASP
polymers were planned to be used in ocular therapy, measure-
ments were performed to determine the release proﬁle of active
ingredients from the gels.2. Materials and methods
2.1. Materials
Imidazole (puriss p.a.) and Ellman’s reagent (5,50-dithiobis(2-
nitrobenzoic acid)) were purchased from Sigma–Aldrich. S-Aspar-
tic acid (99%), dibutylamine (DBA, 99%), methanol (MeOH, 99.9%),
cysteamine hydrochloride (97%), potassium chloride (KCl, 99.5%),
sodium bromate (NaBrO3, 99%), dithiothreitol (DTT, for biochem.),
glutathione (for biochem.), sodium borohydride (for synthesis),
mesitylene (for synthesis) and sulfolane were purchased from
Merck. Phosphoric acid (H3PO4, cc. 85%), hydrochloric acid (HCl,
35%) and dimethylformamide (DMF, pure) were bought from Lach
Ner. N-acetyl-L-cysteine (ACR: 160280250), sodium hydroxide
(NaOH, a. r.) and sodium chloride (NaCl, a. r.) were obtained from
Reanal Hungary. Milli-Q reagent-grade water (j > 18.2 MX cm,
Millipore) was used for the preparation of aqueous solutions. All
reagents and solvents were used without further puriﬁcation.
The modiﬁed and cross-linked polymers were synthetized and all
the measurements were carried out at 25 C, unless otherwise
indicated.
In in vitro and ex vivo experiments, 1 M NaBrO3 solution was
used as a model oxidant. Buffer solutions of pH = 8 were prepared
from imidazole (c = 0.1 M); the pH was adjusted with 1 M HCl. The
pH of the buffer solutions was measured with a pH/ion analyser
(Radelkis OP-271/1, Hungary). The ionic strength of the solutions
was adjusted to 0.15 M with KCl. A phosphate-buffered saline
(PBS) solution of pH = 7.4 was prepared by dissolving 8 g dm3
NaCl, 0.2 g dm3 KCl, 1.44 g dm3 Na2HPO42H2O and 0.12 g dm3
KH2PO4 in distilled water, the pH being adjusted with 0.1 M HCl.
Lachrymal ﬂuid of pH = 7.4 was prepared by dissolving 2.2 g dm3
NaHCO3, 6.26 g dm3 NaCl, 1.79 g dm3 KCl, 96.4 mg dm3
MgCl26H2O and 73.5 mg dm3 CaCl2H2O in distilled water, the
pH being adjusted with 1 M HCl.
Mucin (porcine gastric mucin type II), sodium diclofenac (SD)
and sodium ﬂuorescein were purchased from Sigma Aldrich. No
other modiﬁcations were carried out on porcine gastric mucin type
II. Mucin dispersions were prepared with PBS or simulated lachry-
mal ﬂuid and stirred for 8 h. Hydroxyethylcellulose (HEC) (Natro-
sol Pharm) was bought from Hercules.2.2. Synthesis
The pre-cursor polymer of ThioPASP, polysuccinimide (PSI), was
synthetized by the procedure reported earlier (Gyarmati et al.,
2013). The chemical structure of the PSI was conﬁrmed by 1H
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2H, CH2). The average molecular weight of the PSI, estimated by
measuring the molecular weight of its hydrolysed derivative, PASP,
with HPLC size exclusion chromatography (SEC), proved to be
Mw = 56.1 kDa, PDI = 1.07.
ThioPASP was synthetized by the modiﬁcation of PSI with cys-
teamine hydrochloride in DMF in equimolar amount with DBA as
deprotonating agent (Fig. 1). The procedure was as follows:
0.485 g of PSI (containing 5 mmol of succinimide repeating units)
and 0.114 g (1 mmol) of cysteamine hydrochloride were dissolved
in 9.272 g of DMF under a nitrogen atmosphere. DBA (170 ll,
0.129 g, 1 mmol) was added dropwise to the solution. Solutions
of thiolated PSI were poured between silicon frames (1.0 mm
thickness) on a glass plate and were oxidized by the air into disul-
phide cross-linked PSI gels. After 2 days of oxidation, the PSI gels
were immersed into imidazole buffer of pH = 8 (I = 0.15 M).
Water-swollen, transparent PASP gels were obtained after 3 days
of hydrolysis.
The PASP gels were dissolved by the addition of solid DTT to the
swelling solution. The molar ratio of DTT to thiol groups was 1:1.
Dissolution was complete after 15 min. The reduced ThioPASPs
were dialysed (cut-offMw = 12–14 kDa) against water. Glutathione
was used as antioxidant in a concentration of 1% w/w relative toFig. 1. Synthesis of thiolated poly(aspartic acidthe weight of the polymer. The solid polymers that resulted after
lyophilization were stored at 8 C until further use.
The total thiol content of the polymers was determined by Ell-
man’s assay. 100 ll of polymer solution (c = 100 mM) was diluted
with 200 ll of a freshly-prepared solution of NaBH4 (10% w/w,
pH = 8) and the reduction was performed for 30 min. The excess
of reducing agent was decomposed by the addition of 500 ll of
1 M HCl to the solution, which was neutralized after 30 min with
500 ll of 1 M NaOH. Ellman’s assay was performed by adding
20 ll of Ellman’s reagent (1 M) after dilution of the mixture to
2000 ll with buffer solution of pH = 8. Absorption spectra were
recorded with an Analytic Jena Specord 200 spectrophotometer
(Germany). N-acetylcysteine was used as standard for the calibra-
tion curve. The molar ratio of thiols to repeating units was calcu-
lated to be 7.0% n/n.
2.3. Rheology
ThioPASP was dissolved in PBS and the gelation was initiated by
adding various amounts of oxidant. The precursor solutions of the
hydrogels consisting of the ThioPASP and oxidant were mixed on
the plate of the rheometer. For the mucoadhesive investigation,
the polymer solutions were mixed with a mucin dispersion in) (ThioPASP) from polysuccinimide (PSI).
Fig. 2. Effects of polymer and oxidant concentrations on the storage modulus (G0) of
ThioPASP as a function of the gelation time; the polymer and oxidant concentra-
tions: (4) 7% w/w and 10% w/w; (s) 7% w/w and 20% w/w; (h) 7% w/w and 40% w/
w; (N) 10% w/w and 10% w/w; (d) 10% w/w and 20% w/w; (j) 10% w/w and 40% w/
w, respectively.
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tures 5% w/w). The rheological properties were studied with a
Physica MCR101 rheometer (Anton Paar, Austria). The measuring
device was of cone and plate type (diameter 25 mm, the gap height
in the middle of the cone 0.046 mm, and cone angle 1). The gela-
tion of the ThioPASP polymer was followed at a constant frequency
of 1.0 Hz at a constant strain of 1% at 25 C. Each measurement was
carried out on a freshly-made sample and was started immediately
after the mixing of the compositions. Viscoelastic character was
determined by frequency sweep tests after the gelation, with a
strain of 1% at 25 C. Storage modulus (G0), loss modulus (G00) and
complex viscosity (g⁄) were determined over the angular fre-
quency range from 0.1 to 100 1 s1. The strain value (1%) used in
the measurements was in the range of the linear viscoelasticity
of the gels.
2.4. Swelling of ThioPASP hydrogels
The water absorption capacity of the ThioPASP gels was deter-
mined gravimetrically. 20% w/w mixtures of ThioPASP with differ-
ent oxidant concentrations (1 M NaBrO3, 20% or 40% w/w) were
made in a syringe with a cut ending and held at 4 C for 20 min.
The gel was then pushed out of the cylinder, cut into four equal
parts (for the four parallel measurements) and dried in vacuum
at 30 C to constant weight. The weights of the discs were mea-
sured and they were placed into distilled water at room tempera-
ture. The discs were taken out of the water after deﬁned time
periods, the surplus water was removed by blotting and the
weights of the gels were measured gravimetrically.
2.5. Tensile tests
The measurements were carried out in two different ways;
either the oxidant was added to the polymer solution, or the oxi-
dant was added to the mucin. Tensile tests were performed with
a TA-XT Plus (Texture analyser (ENCO, Spinea, I)) instrument
equipped with a 1 kg load cell and a cylinder probe with a diameter
of 1 cm. Samples were placed in contact with a ﬁlter paper disc
wetted with 50 ll of an 8% w/w mucin dispersion or with excised
porcine conjunctiva. The mucin dispersion was made with simu-
lated lachrymal ﬂuid (pH = 7.4). 10 parallel measurements were
carried out (Sz}ucs et al., 2008).
20 mg of the sample was attached to the cylinder probe and
placed in contact with the biological substrate. A 2500 mN preload
was used for 3 min. The cylinder probe was moved upwards to sep-
arate the sample from the substrate at a preﬁxed speed of
2.5 mmmin1. Measurements were made both with excised por-
cine conjunctiva and with blank (simulated lachrymal ﬂuid). The
porcine conjunctiva was obtained from a slaughterhouse, freshly
detached from the connective tissue and stored at 20 C until
the measurement. After the complete thaw, the conjunctiva was
placed on the previously wetted (with simulated lachrymal ﬂuid)
ﬁlter paper and ﬁxed in the lower probe (Sandri et al., 2006). The
work of adhesion (A, mN mm) was calculated as the area (AUC)
under the ‘‘force versus distance’’ curve (Sandri et al., 2012).
2.6. ‘Wash away’ measurements
To perform the ‘wash away’ measurements, an earlier-
developed modiﬁed Franz diffusion cell was used (Bonferoni
et al., 1999; Rossi et al., 1999). Simulated lachrymal ﬂuid was
streamed through the donor chamber by a HPLC pump, the efﬂuent
ﬂuid being collected in a beaker. The measurements were made on
excised porcine conjunctiva, placed on the acceptor chamber ﬁlled
with distilled water and closed with Paraﬁlm. Filter paper was
impregnated with simulated lachryimal ﬂuid, and positionedbetween the Paraﬁlm and the conjunctiva to keep it hydrated.
The donor chamber was connected to the acceptor chamber (used
to regulate the temperature of the conjunctiva). 250 mg of polymer
gel was used, with sodium ﬂuorescein (0.008% w/w) as the mea-
sured marker. The formulation was prepared in the donor chamber
on the conjunctiva, by adding 5%, 7% or 10% w/w polymer solution
containing sodium ﬂuorescein and 20% w/w oxidant solution. After
10 min, the donor chamber was ﬁlled with lachrymal ﬂuid and a
stream at 1 ml min1 was set up to mimic the lachrymation of
the eye. Measurements were carried out in duplicate and were
made at 35 C, corresponding to the temperature of the eye sur-
face. Lachrymal ﬂuid washings were collected in beakers after 2,
5, 10, 20, 30 and 60 min, and measured with a spectroﬂuorimeter
at 494 nm excitation wavelength and 521 nm emission wavelength
(LS50B, Perkin Elmer) (Sandri et al., 2006). HEC gels under the same
experimental conditions were used as reference.2.7. Drug release measurements
The drug release proﬁle of SD was determined with a vertical
Franz diffusion cell system (Hanson Microette Plus TM). 300 ll of
formulation containing 10% w/w polymer solution with 0.1% w/w
SD and 20% or 40% w/w oxidant solution was placed on a Poraﬁlm
membrane ﬁlter (pore size of 0.45 lm) impregnated with pH 7.4
buffer solution. The two solutions were mixed on the membrane
ﬁlter as a donor phase. PBS (pH = 7.4) was used as acceptor phase
and thermostated at 35 C. Measurements were performed for 24 h
and ﬁve parallel measurements were carried out. 0.8 ml samples
were taken from the acceptor phase by the autosampler and
replaced with fresh PBS. The SD released was quantiﬁed by UV
spectrophotometry at 275 nm (Csizmazia et al., 2011).3. Results and discussion
3.1. Gel formation
The gelation process and the gel structure were characterized
by means of rheology. The effects of the polymer concentration
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or 40% w/w) were studied (Fig. 2).
Gelation did not proceed at polymer concentrations lower than
10% w/w, regardless of the concentration of oxidant. The fastest
gelation and the largest G0 were obtained with 40% w/w oxidant
and 10% w/w ThioPASP. Increase of the oxidant concentration
resulted in a larger number of cross-links via disulphide formation
and a stiffer gel structure. The oxidant concentration also inﬂu-
enced the gelation time: an increase of the weight ratio of the
oxidant accelerated the gelation process. The gelation time can
usually be determined from the cross-point of the moduli G0 and
the G00 (Fatimi et al., 2009; Winter and Chambon, 1986). In our case,
this cross-point could not be observed, because G0 predominated
over G0 throughout the measurement. This might be explained by
the presence of a loosely cross-linked physical network. Prior to
the chemical cross-linking, second-order interactions formed
between the polymer chains, particularly-hydrogen bonds
between the free thiol groups. Consequently, the gelation time
was deﬁned as the time at which a maximum could be observed
in the curve of the differential with respect to time (Fig. 3) (Ma
et al., 2008).
The frequency sweep test was started after full gelation. Table 1
presents G0 and G0 of the formulations at an angular frequency of
1 l s1.
At polymer concentrations lower than 7% w/w, the changes of
the polymer or oxidant concentration did not affect the gelation,
G0 did not change signiﬁcantly and the precursor solutions
remained in the liquid state even after the addition of oxidant (G0
was similar in order of magnitude to G00). A gel structure formed
(G0 was more than an order of magnitude higher than G00) at 7%Fig. 3. The differential curve of the storage modulus (G0) of the 10% w/w ThioPASP
gel with 40% w/w oxidant with respect to time (t).
Table 1
Storage (G0) and loss moduli (G00) at different oxidant and polymer concentrations
(x = 1 s1).
ThioPASP conc. (% w/w) Oxidant conc. (% w/w)
10 20 40
G0 G00 G0 G00 G0 G00
3 0 0.06 0.18 0.02 0.07 0.02
5 0 0.23 0.11 0.02 0.08 0.28
7 0.78 0.37 16.28 1.35 10.20 0.80
10 433.0 11.0 533.0 12.6 637.0 9.1w/w polymer concentration in the case of higher amounts of oxi-
dant (20% and 40% w/w). At high polymer concentrations (7%
and 10% w/w), the values of G0 increased with increase of the poly-
mer concentration and the oxidant amount. The gel obtained at
10% w/w ThioPASP displayed the strongest gel structure, indicating
that the elevation of both the polymer and the oxidant concentra-
tion enhanced the cross-linking density by increasing the concen-
tration of disulphide linkages.
3.2. Swelling of ThioPASP hydrogels
The swelling of the hydrogels was characterized by a gravimet-
ric method. Two formulations of 20% w/w ThioPASP gels were
measured, with different oxidant concentrations (20% and 40% w/
w). During the 6 h measurements, the swollen polymer discs main-
tained their coherent structure and shape, because of the forma-
tion of disulphide linkages between the polymer chains.
Fig. 4 depicts the percentage swelling (%S), calculated from the
following equation (Karadag˘ et al., 2002):
%S ¼ Mt M0
M0
 100 ð1Þ
where M0 is the mass of the dry gel (g) and Mt is the mass of the
swollen gel (g). This value gives information about the water uptake
capacity of the polymer.
The polymers swelled faster initially and the water uptake then
slowed as equilibrium was approached. In the ﬁrst period of the
swelling, there was no signiﬁcant difference between the two sam-
ples, but later the curves diverged. The samples with lower oxidant
concentration contained a lower concentration of disulphide link-
ages. The swelling ability of these hydrogels was larger because
of the lower cross-linking density resulting from the weaker elastic
interactions inside the polymer network. This led to a marked
water uptake of the formulation containing less oxidant. The poly-
mers were able to swell to 6000–7000% of the volume of their dry
mass.
Another important factor involved in the swelling process is the
swelling power (Fswp), which gives information about the mecha-
nism of the swelling (Karadag˘ et al., 2002):
Fswp ¼ Mt M0M0 ¼ Kt
n ð2ÞFig. 4. Swelling kinetics of ThioPASP hydrogels at ((j) 20% w/w and (d) 40% w/w)
oxidant concentrations.
Table 2
Swelling constant and swelling exponents at different oxidant concentrations,
calculated from the power law.
Oxidant conc. (% w/w) K n
20 1.1198 0.874
40 1.5007 0.809
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gel (g) and t is time (min). Table 2 reports the swelling constants (K)
and the swelling exponents (n) of the two oxidant concentrations,
determined by power law ﬁtting to the curve of Fswp vs. t (min).
The mechanism of water uptake is indicated by the value of n. A
value in the range 0.45–0.5 corresponds to Fickian diffusion, while
a value of 0.5–1 means that the diffusion mode is non-Fickian
(Karadag˘ et al., 2002). In our case, non-Fickian diffusion was
observed: the n values were 0.874 and 0.809.
The results of water uptake measurements indicated that the
oxidant concentration did not affect the initial stages of the pro-
cess, but in the second period a larger water uptake was observed
when 20% w/w of oxidant was used.
3.3. Mucoadhesion
3.3.1. Rheology
Rheological synergism between mucin and polymer mixtures
can be proposed as an in vitro parameter through which to deter-
mine the mucoadhesive behaviour of polymers (Hassan and
Gallo, 1990). The rheological method is based on the determination
of the changes in rheological parameters after the mucoadhesive
polymer is mixed with mucin. Hassan and Gallo demonstrated that
a synergistic increase in viscosity could be observed when the
mucoadhesive polymer and mucin were mixed together. This vis-
cosity change, called the bioadhesive viscosity component (gb), is
caused by chemical and physical bonds formed in mucoadhesion.
It can be calculated as follows:
gb ¼ gt  gm  gp ð3Þ
where gt is the viscosity of the mucin-polymer solution system, and
gm and gb are the viscosity components of the mucin and polymer
solution (Caramella et al., 1999; Hassan and Gallo, 1990;
Marschütz and Bernkop-Schnürch, 2002).
More recently, the rheological synergism parameters have been
measured by dynamic oscillatory rheometry. In this case, theFig. 5. Evolution of storage modulus (G0) as a function of time at (a) 7% and (b) 10% w/w
40% w/w was also varied and mucin was (solid symbols) or was not (open symbols) adsynergism parameters can be calculated as follows (Madsen
et al., 1998):
DG0 ¼ G0ðmixÞ  G0ðpolymerÞ þ G0ðmucinÞ
 
ð4Þ
Dg0 ¼ gðmixÞ  gðpolymerÞ þ gðmucinÞ
 
ð5Þ
where G0 is the storage modulus and g⁄ is the complex viscosity of
the systems.
In our work it was difﬁcult to compare the rheological proﬁles
of the polymer solution and the hydrogel because the G0 values
of the ThioPASP and mucin solutions were negligible. It therefore
appeared reasonable to use the relative rheological synergism
parameters, which express the relative increments in viscoelastic-
ity with regard to the polymer and mucin solutions alone (Madsen
et al., 1998):
DG0rel ¼ DG0 G0ðpolymerÞ þ G0ðmucinÞ
 .
ð6Þ
Dgrel ¼ Dg gðpolymerÞ þ gðmucinÞ
 .
ð7Þ
Rheological measurements were performed with different con-
centrations of ThioPASP polymer and mucin. It was presumed that,
if an in situ gelling system is used, the mucin can inﬂuence the
gelation time of the formulation. For this reason, the gelation time
was ﬁrst determined in the presence of mucin, using the same
method as described before. The results are shown in Fig. 5 and
Table 3.
As in the previous measurements without mucin, gelation was
observed only at 7% and 10% w/w ThioPASP. Mucin did not cause
an appreciable difference in the rheological parameters at Thio-
PASP concentrations lower than 7% w/w. In the case of 7% or 10%
w/w polymer, the gelation time was shorter at the lower ThioPASP
concentration, and the gelation time decreased with increasing
concentration of the oxidant. The addition of mucin aided the gela-
tion and in each case the gelation time was shorter in the presence
of mucin. The rate of gelation and the ﬁnal value of G0 were higher
in the presence of mucin.
Frequency sweep tests were performed after gelation to inves-
tigate the interaction between the mucin and the ThioPASP gels.
Fig. 6 presents the variation in G0 with angular frequency for the
formulations with and without mucin. In all cases, mucin aug-
mented the elastic modulus of the samples, indicating that interac-
tions occurred between the polymer and the mucin. The shapes of
the curves (the slopes of the G0 vs. angular frequency curves, whichpolymer concentrations; the oxidant concentration ( ) 10% w/w, (g) 20% w/w, (l)
ded.
Table 3
Gelation time (tg) at different compositions.
ThioPASP conc.
(% w/w)
Oxidant conc.
(% w/w)
tg without
mucin (s)
tg with
mucin (s)
7 10 n. g. n. g.
20 n. g. 450
40 n. g. 420
10 10 780 540
20 330 300
40 150 120
n. g. – No gelation was observed.
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with 10% w/w polymer with or without mucin were similar to each
other. At this concentration, the polymer gels exhibited a densely
cross-linked gel structure even without mucin. Mucin did not
change the rheological proﬁle of the systems. The changes in the
rheological behaviour of the samples containing 7% w/w or less
polymer suggested the formation of a chemically cross-linked
structure between the polymer and mucin chains in addition to
physically entanglement. In a physically entangled structure, the
moduli depend strongly on the frequency: at low frequency, the
G0 values are decreased considerably (Madsen et al., 1998; Ross-
Murphy and McEvoy, 1986). In our case, at lower ThioPASP concen-
trations (and especially 7% w/w), the added mucin decreased theFig. 6. Frequency sweep tests at (a) 3%, (b) 5%, (c) 7% and (d) 10% w/w polymer concent
with (solid symbols) or without mucin (open symbols).slope of the curves, which indicated the occurrence of the cross-
linking of the polymer with the mucin.
Table 4 shows the relative synergism parameters of g⁄ and G0 at
an angular frequency of 1 1 s1.
The stiffness of the gels was larger in the presence of mucin in
each case. At higher polymer concentrations, the relative differ-
ences (DG0 and Dg⁄) were lower at each oxidant content than at
lower polymer concentrations. The mucoadhesive character was
displayed most signiﬁcantly at lower polymer concentrations (3%
and 5% w/w) and especially at 20% w/w oxidant amount. This
result is in accordance with earlier studies in which it was con-
cluded that there is an optimum polymer concentration for
mucoadhesion (Madsen et al., 1998). In our work, this was proba-
bly because a lower amount of oxidant resulted in a loosely, chem-
ically cross-linked structure, and the chains were ﬂexible enough
to be able to form more bonds with the mucin, resulting in a gel-
strengthening effect in the mixture.
3.3.2. Tensile tests
Adhesive strength is deﬁned as the external force required for
the separation of the two interfaces in the tensile test
measurements.
The ﬁrst important step was to determine the ideal oxidant
amount for mucoadhesion. 10%, 20% and 40% w/w of the oxidant
was used In one case the oxidant solution was added to the poly-
mer solution, and in the second case the oxidant was added torations and at ( ) 10% w/w, (g) 20% w/w and (l) 40% w/w oxidant concentrations
Table 4
Relative synergism parameters of viscosity and storage modulus between the
polymer-mucin mixtures.
ThioPASP conc. (% w/w) Oxidant conc. (% w/w) DG0 Dg⁄
3 10 1.88 8.92
20 31.85 36.11
40 22.43 27.03
5 10 6.87 1.65
20 5.28 7.78
40 6.44 2.84
7 10 13.67 12.69
20 2.44 2.44
40 7.46 7.47
10 10 1.61 1.61
20 2.31 2.31
40 2.56 2.56
Fig. 8. (j) Adhesive force (F) and (N) work of adhesion (A) as functions of polymer
concentration.
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thiol groups of the PASP, which therefore has fewer free thiol
groups capable of forming disulphide bonds with the glycoproteins
of the mucin. However, the oxidant is also needed to form bonds
between the polymer and the mucin. These investigations could
help to clarify which procedure is better for ideal mucoadhesion.
Fig. 7 shows the work of adhesion (A, mN mm) of the samples with
10% w/w and 5% w/w polymer concentrations.
The results reveal that A was similar at the two concentrations.
The same formulation prepared in the different ways displayed dif-
ferent mucoadhesive behaviour. It was found that the samples in
which the oxidant was added to the polymer before the contact
with the mucin exhibited greater mucoadhesive strength. An
exception was the formulation with 10% w/w polymer and 40%
w/w oxidant. In this case the samples oxidized in advance demon-
strated lower A values. At this concentration, this is probably due
to the high cross-link ratio, the low number of free thiol groups
for mucoadhesion and the rigid structure of the network.
The formulation with 20% w/w oxidant added to the polymer
solution had the optimal mucoadhesive properties (best A value)
at both polymer concentrations. This amount of oxidant is proba-
bly needed for the optimum gel structure for interpenetration in
the mucin, but still containing sufﬁcient free thiol groups able to
form disulphide bonds with the mucin glycoproteins. With regard
to the results, 20% w/w was chosen as best oxidant concentration.
Other measurements were made with 20% w/w oxidant added to
the polymer solution with blank (lachrymal ﬂuid) and conjunctiva.Fig. 7. Work of adhesion (A) at (a) 10% w/w and (b) 5% w/w polymer concentrations; samp
P and M stand for ThioPASP and mucin, respectively.Measurements were also made with 3% and 7% w/w polymer
(Fig. 8).
Fig. 8 shows that A increased continuously as the concentration
was elevated, while the adhesive force (F, mN) reached a maximum
at 7% w/w polymer. It was earlier established (Park and Munday,
2002) that the F depends on the formation of chemical bonds
between the functional groups of the polymer investigated and
the mucin, whereas A is dependent on the formation of chemical
bonds and also on mechanisms such as physical entanglement or
interpenetration. In our work, the chemical bonds probably have
a larger effect at lower polymer concentration, and it is likely that
covalent bonds and secondary bonds were formed with the mucin
glycoproteins. Thus, F increased continuously with increasing poly-
mer concentration. At high polymer concentration, the potential
for chemical bonds reached a maximum because the free thiol
groups were saturated at the interface. Accordingly, a plateau
was observed in the F vs. concentration curve. A did not reach a
maximum, but increased continuously, because interpenetration
prevails in the process of mucoadhesion rather than chemical
bonding at higher polymer concentrations. In our case, the Thio-
PASP gel at higher concentration has more thiol groups and moreles are labelled as x  P or x M, where x is the oxidant concentration in % w/w, and
Fig. 9. (a) ThioPASP and (b) HEC containing the model drug. Polymer concentrations: (h) 5% w/w, (s) 7% w/w and (4) 10% w/w.
Fig. 10. Release of model drug, SD from ThioPASP gel at (j) 20% w/w and (d) 40%
w/w oxidant concentrations.
Table 5
Release exponent (n) and kinetic constant (k) at two oxidant concentrations.
Oxidant conc. (% w/w) n k
20 0.6561 8.8906
40 0.5815 10.322
G. Horvát et al. / European Journal of Pharmaceutical Sciences 67 (2015) 1–11 9cross-links resulting in a gel structure, which induces increased
swelling, allowing deeper and improved interpenetration.
These tensile test results can be correlated to the rheological
results, where the changes in the shape of the frequency sweep
curves could be observed up to 7% w/w polymer concentration,
which indicated the formation of chemical cross-links
(Hägerström and Edsman, 2003).
3.3.3. ‘Wash away’ measurements
‘Wash away’ ex vivo measurements mimic the lachrymation of
the eye, under conditions relatively close to real mucoadhesive cir-
cumstances of the eye. The amount of sodium ﬂuorescein washed
away from the porcine conjunctiva can indicate the amount of the
dosage form remaining on the surface. In our work, HEC gels were
used as reference.
It can be observed in Fig. 9a that increase of the ThioPASP con-
centration was accompanied by a slight decrease in the amount of
model drug washed away. These differences were not pronounced
after 1 h. In the case of the reference systems (HEC gels, Fig. 9b),
the observations were similar; the gel with the lowest HEC concen-
tration underwent the fastest washing out. Comparison of the
ThioPASP systems with the HEC gels indicated that the ThioPASP
formulations have a longer residence time, because 40% w/w of
the model drug remained on the conjunctiva, in contrast with
10–30% w/w for the reference systems.
3.4. Drug release measurements
Drug release measurements were performed with a vertical
Franz diffusion cell system with gels containing 10% w/w polymer,
SD and 20% or 40% w/w oxidant. Fig. 10 shows the amount of drug
released (% w/w) during time.
In the ﬁrst hour, the diffusion of the SD was fast and there was
no signiﬁcant difference between the two formulations. After 5 h,
the release proﬁles became dissimilar in the cases of different con-
centrations of oxidant, and the formulation with 20% w/w oxidant
released a larger amount of the SD. These results correspond with
the results of the swelling measurements. The formulation with
20% w/w oxidant has a higher water uptake, suggesting a lower
cross-linking density, and the SD is therefore able to diffuse
through this structure more easily.
The swelling-controlled drug release mechanism can be charac-
terized with the following equation:
Mt
M/
¼ ktn ð8Þwhere Mt/M/ is the fraction of drug released, k is the kinetic con-
stant and n is the release exponent describing the mechanism of
the release (Peppas et al., 2000). These values were determined
from the equation of the power law ﬁtted to the curve of the
amount of drug released (% w/w) against time (min) (Table 5).
In our case, we have a non-Fickian release mechanism, because
the value of n is between 0.5 and 1, and these results also corre-
spond with our swelling results (Table 2). Non-Fickian (anomalous)
transport occurs due to a coupling of Fickian diffusion and a poly-
mer relaxation. In the anomalous processes of drug release, Fickian
diffusion through the hydrated layers of the matrix and polymer
chain relaxation/erosion are both involved. The contribution of
these two mechanisms to the overall release are considered to be
10 G. Horvát et al. / European Journal of Pharmaceutical Sciences 67 (2015) 1–11additive. The Fickian contribution to the overall release process is
decreasing with the increasing amount of the released drug. Thus,
the relaxation of the polymer chains becomes more pronounced,
which is expected since water is taken up simultaneously with
drug release, and this water enables polymer chain relaxation
(Baumgartner et al., 2006; Park and Munday, 2002; Peppas et al.,
2000; Peppas and Buri, 1985; Ritger and Peppas, 1987). During
the drug release, our polymer gels of 10% w/w placed on the mem-
brane was continuously swelling, which led to a simultaneous
absorption of the water and desorption of drug via a swelling-
controlled diffusion mechanism. The combination of diffusion,
swelling, and relaxation is responsible for the non-Fickian release
mechanism (Lee, 1985).
The advantage of these formulations is the rapid drug release in
the ﬁrst hour, followed by a prolonged release. This is important in
therapy, because a higher dose is needed immediately after the
application, to reach the therapeutic dosage, after which a sustain-
ing dosage is required. From the aspect of ophthalmic preparations,
this can increase patient compliance.
4. Conclusion
The generally poor bioavailability of ophthalmic formulations
can be improved by new formulations with a prolonged residence
time. In situ gellable ThioPASP hydrogels were fabricated with the
aim of obtaining delivery vehicles with increased adhesion to the
eye surface and these hydrogels were characterized in terms of
gelation time, viscoelastic behaviour, mucoadhesion and drug
release. Mucin exhibited a strong effect on cross-link formation,
and the ThioPASP gels displayed strong mucoadhesion, especially
at lower polymer concentrations (3%, 5% w/w). The addition of a
small amount of oxidant improved the mucoadhesion, as indicated
by the A values during the tensile tests, because of the formation of
a gel structure with a considerable number of free thiol groups. The
ThioPASP gels demonstrated high resistance against lachrymation
of the eye, which also conﬁrmed the strong mucoadhesion. SD
could be encapsulated into the ThioPASP polymers during forma-
tion of the gel structure and underwent rapid release in the ﬁrst
hour during in vitro measurements, which was followed by a sus-
tained release of the drug for a further 23 h. This drug release pro-
ﬁle and the strong mucoadhesion excellently illustrate the
potential of the application of the ThioPASP polymer as an in situ
gelling, ocular drug delivery formulation for a once-daily dose
administration.
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a  b  s  t  r  a  c  t
Hyaluronic  acid  (HA)  and  its derivatives  play important  roles  in  many  ﬁelds  of  therapy,  such  as  arthritis
treatment,  plastic  surgery,  dermatology,  otology,  ophthalmology,  etc.  With  a view  to increase  the  beneﬁ-
cial properties  of  HA  in  ocular  drug  delivery,  many  types  of chemical  structural  modiﬁcations  have  been
performed.  In  the course  of  our  research  work,  we  characterized  nanosized  cross-linked  –  (CLNaHA),
linear  sodium  hyaluronate  (NaHA)  and  zinc-hyaluronate  (ZnHA),  as potential  ocular  drug  delivery  sys-
tems.  The  aim  was  to determine  the  inﬂuence  of  the  structure  on  biocompatibility,  mucoadhesion  and
drug  release.  The  structure  was characterized  by  means  of rheology.  The  cytotoxicity  of  the  samples  was
determined  on rabbit  corneal  epithelial  cells  (RCE)  by the  MTT  test. Mucoadhesion  measurements  were
made by a rheological  method  in  vitro and  by  tensile  tests  in  vitro  and  ex  vivo.  The  release  of  sodiumytotoxicity
cular drug release
diclofenac,  a  frequently  used  non-steroidal  anti-inﬂammatory  drug  with  low  bioavailability,  from  the
gels was  determined  with  a vertical  Franz  diffusion  cell. The  results  demonstrated  that  all  three  deriva-
tives have  adequate  mucoadhesive  properties  and  their  rapid  drug  release  proﬁles  are  beneﬁcial  in ocular
therapy.  Thanks  to  these  properties,  the  bioavailability  of  the ophthalmic  preparations  can  be  increased,
especially  with  the  application  of CLNaHA.. Introduction
Hyaluronic acid (HA), a natural linear anionic polysaccharide
glycosaminoglycan), is the main component of the extracellu-
ar matrix of the connective tissue and has been proved to be
iodegradable, biocompatible, non-toxic, non-immunogenic and
on-inﬂammatory. Its structure is based on two disaccharide units,
-glucuronic acid and N-acetyl-d-glucosamine, polymerized into
arge macromolecules of over 30,000 repeating units. Under phys-
ological conditions, HA is present in the form of its sodium salt
Ganguly et al., 2014; Lai and Tu, 2012; Mayol et al., 2008; Price
t al., 2007; Vasi et al., 2014).
HA has a high capacity for lubrication, water binding and
ater retention, and in solution it has characteristic rheological
∗ Corresponding author.
E-mail address: csanyi@pharm.u-szeged.hu (E. Csányi).
ttp://dx.doi.org/10.1016/j.ijpharm.2015.08.024
378-5173/© 2015 Elsevier B.V. All rights reserved.© 2015  Elsevier  B.V.  All  rights  reserved.
properties (Lai and Tu, 2012; Saettone et al., 1991). Thanks to
its unique properties, HA derivatives are used in many ﬁelds:
osteoarthritis treatment, tissue engineering, otology and plastic
surgery. Exogenously applied HA exerts a beneﬁcial effect on
several mechanisms of wound healing (Price et al., 2007).
In 1934, Karl Meyer and John Palmer, at the Columbia Univer-
sity, New York, isolated a new polysaccharide from the vitreous
humour of cows and they called it “hyaluronic acid” (Meyer and
Palmer, 1934). Over the following decades, Endre Balazs extracted
hyaluronic acid from rooster combs and puriﬁed it for medi-
cal application in humans and suggested to use it in ophthalmic
surgery (Balazs et al., 1972). During the ocular surgery, ophthalmic
viscosurgical devices (OVD), containing hyaluronic acid, are able
to maintain the deep chamber, to aid in tissue manipulation,
to enhance visualization and to protect the corneal endothelium
(Balazs and Stegmann, 1979).
As topical use, HA is applied in the treatment of dry eye and
Sjögren’s syndrome. In higher concentrations, with a gel-like
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tructure, HA can be used to prevent the desiccation of the cornea
nd it can be utilized as a carrier for antibiotics to the eye, because
 formulation with relatively high viscosity and mucoadhesive
roperties, prevents the drug from being washed out by the tears
nd the drug release is therefore prolonged. This is especially
mportant in ocular therapy, because the bioavailability of the
ormulations, available on the market, is merely 2–10%, which
ould be increased by increasing the residence time on the eye
Ludwig, 2005; Price et al., 2007; Vasi et al., 2014).
Ocular mucoadhesion occurs when the polymer interacts with
he mucin covering the conjunctiva and corneal surfaces of the eye.
he ocular mucus has a turnover time of 15–20 h and plays a role in
ydration, cleaning, lubrication and protection against pathogens
nd foreign substances. During the formulation of a mucoadhesive
rug delivery system, eye movements and blinking have to be taken
nto consideration, because these create a shear force which may
hin or dislodge the formulation. HA can serve as an appropriate
ehicle thanks to its special viscoelastic rheological proﬁle. Dur-
ng blinking, the HA molecules align with each other and spread
ver the surface of the cornea. Between blinks, the molecules form
 tangled meshwork, resulting in a less elastic and more viscous
olution that stabilizes the pre-corneal tear ﬁlm and maximizes
he residence time of the formulation on the surface (Robinson and
lynek, 1995; Scheuer et al., 2010; Vogel et al., 2010).
Beside this viscoelastic property, interpenetration and sec-
ndary bond formation between the HA molecules and the mucin
lso play an important role in the process of mucoadhesion.
The goal of our work was to compare three types of HA deriva-
ives, a nanosized cross-linked sodium salt (CLNaHA), a linear
odium salt (NaHA), present in living tissues, and a linear zinc salt
ZnHA), as potential ocular mucoadhesive drug delivery systems.
In earlier studies, nano-sized CLNaHA was prepared by a
arbodiimide technique, based on covalent crosslinking via the car-
oxyl groups of the HA chains with a diamine in aqueous medium at
oom temperature. Through crosslinking of the HA molecules, the
egradation time can be prolonged and the mechanical stability
an be improved (Berkó et al., 2013; Bodnár et al., 2009; Kafedjiiski
t al., 2007; Maroda et al., 2011; Vasi et al., 2014).
Another HA modiﬁcation involves Zn(II)-HA complex formation
y adding Zn(II) chloride to an aqueous NaHA solution at pH 5.5–6.5.
eside the typical HA effects, ZnHA has scavenger, bactericidal, bac-
eriostatic and fungicidal effects, which are useful in ocular therapy,
ecause the traditional preservative may  be omitted from the for-
ulation (Illés et al., 2002; Nagy et al., 1998).
The mucoadhesive properties of CLNaHA, NaHA and ZnHA were
emonstrated by rheological and tensile test methods in vitro and ex
ivo. The cytotoxicity of the derivatives was determined by the MTT
est on rabbit corneal epithelial cells. Besides these measurements,
t was important to determine the drug release proﬁles, because of
heir potential application as drug delivery systems by instillation
nto the cul-de-sac or on the surface of the eye. Sodium diclofenac
SD), a drug generally used in ophthalmic practice, was used to
nvestigate CLNaHA, NaHA and ZnHA as carrier molecules.
. Materials and methods
.1. Materials
NaHA (MW:  4350 kDa) and ZnHA (MW:  498 kDa) were pur-
hased from Richter Gedeon Ltd. (Budapest, Hungary), and
LNaHA was prepared by BBS Biochemicals LLC (Budapest,
ungary). 2,2-(Ethylenedioxy)bis(ethylamine), 1-[3(dimethyla-
ino)propyl]-3-ethylcarbodiimide methiodide (CDI), mucin
porcine gastric mucin type II), MTT  (3-(4,5-dimethylthiazol-2-
l)-2,5-diphenyltetrazolium bromide), dimethyl sulfoxide (DMSO)harmaceutics 494 (2015) 321–328
and sodium diclofenac (SD) were purchased from Sigma Aldrich
(USA). A phosphate-buffered saline (PBS) solution of pH = 7.4 was
prepared by dissolving 8 g dm−3 NaCl, 0.2 g dm−3 KCl, 1.44 g dm−3
Na2HPO4·2H2O and 0.12 g dm−3 KH2PO4 in distilled water, the
pH being adjusted with 0.1 M HCl. Lacrimal ﬂuid of pH = 7.4 was
prepared by dissolving 2.2 g dm−3 NaHCO3, 6.26 g dm−3 NaCl,
1.79 g dm−3 KCl, 96.4 mg  dm−3 MgCl2·6H2O and 73.5 mg  dm−3
CaCl2·H2O in distilled water and the pH was  adjusted with 1 M HCl.
2.2. Preparation of CLNaHA nanoparticles
The ﬁrst step of CLNaHA nanoparticle preparation was to make
a 1 mg  ml−1 NaHA (MW:  4350 kDa) solution with pH adjusted to
5.5. Mixing of NaHA solution with diamine solution (1.0%, v/v) at
room temperature for 30 min  was followed by the dropwise addi-
tion of CDI solution, after which the reaction mixture was  stirred for
24 h at room temperature. The aqueous system, containing CLNaHA
nanoparticles was  puriﬁed by dialysis for 7 days against distilled
water and the system was ﬁnally freeze-dried. The ﬁnal cross-
linking ratio was 25% (Berkó et al., 2013; Bodnár et al., 2009; Maroda
et al., 2011).
2.3. Gel formulation
In ophthalmic preparations, solvents buffered at pH 7.4 are often
used. Gels of CLNaHA, NaHA and ZnHA were prepared in concen-
trations of 0.5, 1 and 2% (w/w). The samples were stored at 4 ◦C
and were used for the measurements after 3 days. For cytotoxic-
ity determination, formulations of 4% (w/w) were used in 20-fold
dilution. For drug release determination, 1% (w/w) formulations of
CLNaHA, NaHA or ZnHA were prepared containing 0.1% (w/w) SD.
First SD was  dissolved in PBS followed by the addition of CLNaHA,
NaHA or ZnHA to the solution and the samples were stored for 3
days.
2.4. Rheology
Measurements were carried out with CLNaHA, NaHA and ZnHA
gels and their mixtures with mucin dispersion for the mucoadhe-
sive investigation (the mucin concentration in the mixture was 5%,
w/w) (Horvát et al., 2015). A Physica MCR  101 rheometer (Anton
Paar, Austria) with a cone-plate measuring device (CP-50, Anton
Paar, Austria; cone angle = 1◦; the gap height in the middle of
the cone 0.046 mm)  was used for rheological measurements. Flow
curves were determined at 35 ± 0.1 ◦C by increasing the shear rate
from 0.1 to 100 s−1 and then decreasing it from 100 to 0.1 s−1
(Gratieri et al., 2010). Frequency sweep tests were performed to
determine the viscoelastic character. Measurements were made
over the frequency range from 0.01 to 100 Hz, whereby the storage
modulus (G′), loss modulus (G′′) and viscosity () were determined.
The strain value (1%) used in the measurements was  in the range
of the linear viscoelasticity of the gels.
2.5. Cytotoxicity
For the cytotoxicity measurements, the RCE cell line (rabbit
corneal epithelial cells) was  used, obtained from the European Cell
Culture Collection (No 95081046, ECACC, Salisbury, UK). For the
cytotoxicity determination, the MTT  test was performed, which
is based on the conversion of MTT  in formazan by the mitochon-
drial dehydrogenases of the vital cells. The RCE cell suspension was
seeded in wells at a density of 7500 cells/well and was kept at 37 ◦C
in an atmosphere of 95% air and 5% CO2 and 95% relative humidity
for 24 h to ensure attachment of the cells to the wells.
CLNaHA, NaHA and ZnHA gels were prepared in 4% w/w concen-
tration and, after 20-fold dilution, were brought into contact with
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ells for 3 h. The samples were then removed and 50 l MTT  at
.25 g ml−1 and 150 l HBSS (Hank’s Buffered Salt Solution, pH 7.4)
as brought into contact with cells for 3 h. After the contact time,
he reagent was removed from the wells and the cells were washed
ith HBSS to remove the samples and the unreacted MTT  solution,
ollowed by the addition of DMSO. The cell plate was shaken for
0 s and the absorbance was determined at 570 nm with the ELISA
late reader (ImarkAbsorbance Reader, Biorad, I), with the refer-
nce wavelength set at 690 nm.  Cell viability was calculated as the
 ratio of the absorbance of each sample and the absorbance of
he cells kept in contact with HBSS (control). Eight replicates were
erformed for each sample (Sandri et al., 2012; Mori et al., 2014).
.6. Tensile test
A TA.XT Plus (Texture analyser, ENCO, Spinea, I), equipped with
 1 kg load cell and a cylinder probe with a diameter of 1 cm,
as used for mucoadhesion measurements. In vitro measurements
ere carried out with 50 l 8% (w/w) mucin dispersion (prepared
ith simulated lacrimal ﬂuid) (Horvát et al., 2015); ex vivo mea-
urements were made with excised porcine conjunctiva and blank
easurements with 50 l simulated lacrimal ﬂuid. The porcine
onjunctiva, obtained from a slaughterhouse, was  freshly detached
rom the connective tissue and stored at −20 ◦C until measure-
ents. After complete thawing, the conjunctiva was placed on the
reviously wetted (with simulated lacrimal ﬂuid) ﬁlter paper and
xed in the lower probe. 20 mg  samples were attached to the cylin-
er probe, which was put in contact with the biological substrate
t a preload of 2500 mN for 3 min  at 35 ± 0.5 ◦C. The cylinder probe
as moved upwards to separate the sample from the substrate at a
reﬁxed speed of 2.5 mm min−1. The work of adhesion (A, mN mm)
as calculated as the area under the force versus distance curve
Sandri et al., 2006, 2012).
.7. Drug release
A vertical Franz diffusion cell system (Microette Plus, Hanson,
SA) was used to determine the SD release proﬁle. 0.3 g sam-
les containing 0.1% (w/w) SD were placed as donor phase on the
reviously impregnated (in pH 7.4 PBS) Poraﬁl® membrane ﬁlter
Macherey–Nagel GmbH & Co., Germany; pore size 0.45 m).  The
cceptor phase was PBS (pH = 7.4), thermostated at 35 ◦C. Measure-
ents were performed for 6 h. 0.8 ml  samples were taken from the) CLNaHA, () NaHA and ( ) ZnHA; and (b) viscosity curves of () CLNaHA, ()
acceptor phase by the autosampler and replaced with fresh PBS. The
amount of SD released was quantiﬁed by UV spectrophotometry at
275 nm (Berkó et al., 2013; Csizmazia et al., 2011).
2.8. Statistical analysis
The results were evaluated and analyzed statistically with
GraphPad Prism version 5 software. Two-way ANOVA analysis was
applied with Bonferroni post-tests (Patterson et al., 2010). The val-
ues are expressed as means ± standard deviation (SD). A level of
p ≤ 0.05 was  taken as signiﬁcant, p ≤ 0.01 as very signiﬁcant, and
p ≤ 0.001 as highly signiﬁcant.
3. Results and discussion
3.1. Rheology of the gels
The viscoelastic characters of the CLNaHA, NaHA and ZnHA were
determined by frequency sweep testing in the frequency range
from 0.01 Hz to 100 Hz. G′ corresponds to the elastic and G′′ to
the viscous behaviour of the measured samples. The cross-over
points of these curves show the transition from viscous to elas-
tic behaviour (Berkó et al., 2013; Cowman and Matsuoka, 2005).
Fig. 1 shows (a) the frequency sweep test and (b) viscosity results
on the measured samples at 1% (w/w) polymer concentration.
The highest viscosity was  observed for NaHA, which corre-
sponds to its long linear structure. CLNaHA exhibited a lower
viscosity, because it contains intrachain cross-linking, which
produces nanoparticles with a particle size <110 nm (Maroda et al.,
2011), and ZnHA had the lowest viscosity. The structure of the ZnHA
molecules in the formulation probably involves fewer entangle-
ments, and this causes lower viscosity.
CLNaHA and NaHA displayed viscoelastic behaviour, acting as
viscous solutions in the lower frequency range, and demonstrat-
ing elastic properties at higher frequency. The cross-over point
for NaHA was  seen at lower frequency than that for CLNaHA,
from which it can be concluded that CLNaHA showed less elastic
behaviour. In contrast with CLNaHA and NaHA, ZnHA behaved as
a viscous ﬂuid; G′′ predominated over G′, and no cross-over point
could be detected.
The shear thinning and frequency dependent (time-dependent)
behaviour of HA have been noted by several publications (Balazs
and Denlinger, 1985; Milas et al., 2001). The polymer solutions
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howed a Newtonian plateau with decreasing shear rate. This
lateau viscosity is known as zero-shear viscosity. Increasing the
hear rate over the rate at which HA chains can relax, the chains
emain distorted and the changes of viscosity refer to shear-
hinning behaviour. Both shear-thinning and time-dependent
ehaviour, where elastic dominance (G′ > G′′) can be seen at high
requencies but viscous dominance (G′′ > G′) can be observed at low
requencies, are related to the relaxation time of HA. In case of
emi-dilute HA solutions the relaxation time depends on the con-
entration, the solution conditions and the molecular weight of HAs
Cowman and Matsuoka, 2005).
This viscoelastic behaviour of the derivatives is very beneﬁcial
or purposes of ocular therapy because they can easily spread over
he eye surface during blinking and prolong the residence time of
he drug delivery system.
.2. Cytotoxicity
Fig. 2 shows the results of the biocompatibility determination of
LNaHA, NaHA and ZnHA on RCE cells by the MTT  test. As control,
BSS was used.
CLNaHA and NaHA are biocompatible: the cell viability was
0.84 ± 9.90% in case of CLNaHA and 103.90 ± 6.56% in the case of
aHA; ZnHA displayed lower biocompatibility (cell viability was
4.39 ± 11.91%) after a 3 h contact time.
Zinc is an essential metal, with important roles in the regulations
nd structure and as a cofactor for many enzymes. Under in vivo
onditions, it is non-toxic, thanks to the homeostatic regulatory
echanisms. The maintenance of homeostasis in cell lines is difﬁ-
ult, which leads to a decrease in cell viability. It was established
arlier that tolerance to zinc can be dependent on the rate of zinc
ptake and the capacity of the protective mechanism (Borovansky
nd Riley, 1989; Bozym et al., 2010; Mehr, 2011; Ugarte and
sborne, 2001; Ugarte et al., 2013).
Our results demonstrated that CLNaHA and NaHA are biocom-
atible. Although ZnHA exhibits lower biocompatibility in the RCE
ell line, under in vivo conditions it may  have better biocompatibil-
ty thanks to the in vivo homeostatic mechanisms.
.3. Mucoadhesion.3.1. Rheology
The mucoadhesive nature of a sample can be determined by the
heological method developed by Hassan and Gallo. During thisharmaceutics 494 (2015) 321–328
measurement, the sample is mixed with mucin dispersion and the
synergistic increase in rheological parameters is determined, which
is caused by chemical and physical bond formation between the
mucin and the bioadhesive component. This synergism parameter
(bioadhesive viscosity component, b) can be calculated from the
following formula (Caramella et al., 1999; Hassan and Gallo, 1990;
Madsen et al., 1998):
b = t − m − p (1)
where t is the viscosity of the mucin-polymer solution system, and
m and p are the viscosity components of the mucin and polymer
solution, respectively.
Measurements were performed at three different concentra-
tions; 0.5, 1 and 2% w/w.  Flow curves of the CLNaHA, NaHA and
ZnHA formulations and their mixtures with mucin are presented
in Fig. 3.
The measured derivatives and their mixtures with mucin
displayed shear-thinning behaviour, with the shear viscosity
dependent on the degree of shear load and the ﬂow curve exhibit-
ing a decreasing slope, which is typical for polymer systems. At the
beginning of the test, where the shear values are low, the macro-
molecules are in the state of the lowest level of energy consumption
looking like a coil. Each coil is entangled with neighbouring macro-
molecules. Increasing the shear values, the macromolecules partly
disentangle, orient in the shear direction, which lowers their ﬂow
resistance. In the third part of the test, where the shear values
reduce, fast gel structure regeneration can be observed (Mezger,
2002).
Mucoadhesive behaviour was  observed for all formulations at all
three concentrations. The shear stress values of the mixtures (gel
and mucin) were higher than those of the HA derivatives without
mucin. These results correspond to the phenomenon that interac-
tions can occur between the polymers and the mucin. Mucin has a
gel-strengthening effect, because more network links are created
by entanglements and secondary bond (hydrogen-bond) forma-
tion. The calculated synergism parameters of viscosity at a shear
rate of 100 s−1 are illustrated in Fig. 4.
The calculated values revealed that the mucoadhesive
behaviour increased with the increase of the polymer con-
centration. At higher concentration, an adequate gel structure is
probably formed, which can easily interpenetrate and form sec-
ondary bonds with the mucin. CLNaHA is a nanoparticulate system
which contains intrachain cross-linking, enabling the CLNaHA
molecules to interpenetrate more easily than the other two  deriva-
tives at all three concentrations. At 0.5% (w/w), CLNaHA exhibited
more marked mucoadhesion than those of NaHA and ZnHA, which
is very beneﬁcial in the case of eye drops for instillation. ZnHA
at lower concentrations has a liquid-like structure, which causes
difﬁculty in interpenetration, while at higher concentration (2%,
w/w) it has a gel-like structure and its mucoadhesive behaviour is
similar to those of the other derivatives. At 1 and 2% (w/w), there
is no signiﬁcant difference in the mucoadhesivity of CLNaHA and
NaHA.
The results of rheological measurements indicated that CLNaHA,
NaHA and ZnHA are mucoadhesive, especially at higher polymer
concentration. The pronounced mucoadhesive nature of CLNaHA
at 0.5% (w/w) is very advantageous in ocular therapy, because the
washing-out from the eye by lacrimation after instillation demands
more effort as compared with formulations without mucoadhesive
polymers. Thanks to the mucoadhesive and viscoelastic behaviour
of CLNaHA, NaHA and ZnHA, they are able to prolong the residence
time on the ocular surfaces.3.3.2. Tensile test
Tensile test involves measurement of the force of detachment
and the total work of adhesion needed to separate the surfaces,
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hich results from the area under the force–distance curve (Woertz
t al., 2013). Many factors inﬂuence the phenomena of mucoad-
esion, e.g. physiological factors (mucin turnover, diseases, etc.),
nvironment-related factors (pH, contact time, etc.) and polymer-
elated factors (the molecular weight, the ﬂexibility of the polymer
hains and the concentration of the polymer, etc.). The studies by
ark and Munday established the dependence of the adhesive force
f chemical bond formation between the polymers and mucin,
hereas the work of adhesion is dependent not only on chemical
ond formation, but also on physical mechanisms (entangle-
ents and interpenetration) (Park and Munday, 2002; Vasir et al.,
003).
The adhesive force (F) and the work of adhesion (A) of CLNaHA,
aHA and ZnHA were determined in contact with mucin (Fig. 5).
The values of F for all three derivatives did not increase with
ncrease in concentration. Their potential for chemical bond for-
ation had reached the maximum and the adhesive force could
ot increase. The values of A increased with increase of the poly-
er  concentration thanks to the physical mechanisms betweenhe polymer and the mucin. These results correspond with the
henomena described by Park and Munday. There was  no signiﬁ-
ant difference between the values of F and A in the cases of CLNaHA
nd NaHA. ZnHA does not have a gel-like structure at 0.5% (w/w)
ig. 4. Calculated synergism parameter values of viscosity at a shear rate of 100 s−1.) and ( ) 2% (w/w), with mucin (open symbols) or without mucin (solid symbols).
which would enable it to interpenetrate and form entanglements
in the same way as for the other two derivatives. At higher ZnHA
concentrations, F and A increased because of the gel-like structure,
but not so strongly as for the other two derivatives.
The tensile test results correlated with the results of the rheolo-
gical measurements. In both cases, CLNaHA and NaHA showed the
highest capability for mucoadhesive bond formation, and ZnHA the
lowest.
Ex vivo measurements were also performed. Gels were placed
in contact with excised porcine conjunctiva (Fig. 6). These mea-
surements related to conditions closer to the real mucoadhesive
circumstances of the eye.
The values of A were at least twice as high in the ex vivo mea-
surements as those measured with mucin in the case of the in vitro
measurements. This is beneﬁcial for ophthalmic therapy, because
it can be predicted that the mucoadhesion of the gels will be higher
on the surface of the eye. In these measurements, CLNaHA gave sig-
niﬁcantly higher A values than those of the other two derivatives.
Its nanosized structure leads to easier and deeper interpenetration
and easier chemical bond formation with the mucus layer of the
eye. The pronounced mucoadhesive behaviour of CLNaHA at 0.5%
(w/w) was also seen in the ex vivo measurements, proving the pos-
sibility of prolonging the residence time on the eye surface even
at low CLNaHA concentration. NaHA and ZnHA under ex vivo cir-
cumstances were probably not able to interpenetrate to the same
extent as CLNaHA, but they showed increase in mucoadhesion and
no signiﬁcant difference was  observed between them.
3.4. Drug release
The drug release from CLNaHA, NaHA and ZnHA at 1% (w/w)
polymer concentration containing 0.1% (w/w) SD was measured
with a vertical Franz diffusion cell. Fig. 7 shows the amount of drug
released (% w/w)  during time (h).
In the ﬁrst hour of measurements, a rapid diffusion of SD was
observed from all three formulations, but their release proﬁles then
separated. Statistical analysis showed that there was no signiﬁcant
difference between CLNaHA and NaHA in the ﬁrst hour, but CLNaHA
later released a higher amount of SD as compared with NaHA. This
can be explained by the easier diffusion of SD from the CLNaHA
gels, due to the smaller particle size and lower viscosity. NaHA has a
linear structure and SD probably cannot diffuse to such an extent as
in the case of CLNaHA. ZnHA released a signiﬁcantly lower amount
of SD, even in the ﬁrst hour, possibly because interactions may occur
between SD and ZnHA. This needs to be investigated, but did not
constitute part of the present research work.
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Fig. 5. Adhesive force (a) and work of adhesion (b) of () CLNaHA, () NaHA and () ZnHA as a function of the concentration of the polymer in contact with mucin (***p ≤ 0.001
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aighly  signiﬁcant compared with CLNaHA and NaHA).
The drug release mechanism can be characterized with the fol-
owing equation:
Mt
M∞
= ktn (2)
here Mt/M∞ is the fraction of drug released, k is the kinetic
onstant and n is the release exponent describing the mecha-
ism of the release (Chaturvedi et al., 2011; Kajjari et al., 2014;
eppas et al., 2000). The slopes were determined by power law
tting to the curve of the released drug amount (% w/w)  versus
ime (h) of CLNaHA, NaHA and ZnHA in the ﬁrst hour of the
easurements.
The slopes in the ﬁrst hour indicated non-Fickian drug release in
he cases of CLNaHA (n = 0.6081, R2 = 0.9996) and NaHA (n = 0.5814,
2 = 0.9997), because the n values were between 0.5 and 1. In
hese anomalous processes of drug release, both, Fickian diffusion
ig. 7. Release of SD from () CLNaHA, () NaHA and () ZnHA (*p ≤ 0.05, signiﬁcant
ompared with NaHA; and ***p ≤ 0.001, highly signiﬁcant compared with CLNaHA
nd NaHA).through the hydrated layers of the matrix and polymer chain relax-
ation/erosion are involved. The Fickian contribution to the overall
release process decreases with increasing amount of drug released.
Thus, the relaxation of the polymer chains becomes more pro-
nounced, which is expected since water is taken up simultaneously
with drug release, and this water leads to polymer chain relax-
ation (Baumgartner et al., 2006; Mundargi et al., 2008; Park and
Munday, 2002; Peppas and Buri, 1985; Peppas et al., 2000; Ritger
and Peppas, 1987). In the case of ZnHA (n = 1.0013, R2 = 0.9988)
zero-order kinetics was observed, which conﬁrms the possibility
of interactions between SD and ZnHA.
In conclusion, it can be established that all the derivatives
undergo rapid release, and up to 6 h release more than 65% (w/w)  of
the SD. This release proﬁle is beneﬁcial in ocular therapy, because
the therapeutic dosage can be reached at the beginning of the appli-
cation, which is followed by a sustaining dosage.
Fig. 6. Work of adhesion of () CLNaHA, () NaHA and () ZnHA as a function
of  the concentration of the polymer in contact with excised porcine conjunctiva
(***p  ≤ 0.001, highly signiﬁcant compared with CLNaHA).
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. Conclusion
HA derivatives are widely used and researched in many thera-
eutic ﬁelds, due to their valuable properties such as a high capacity
or lubrication, water binding and water retention, and they also
lay an important role in wound healing. In our work, nanosized
LNaHA, NaHA and ZnHA were investigated. They have different
tructures, which inﬂuence their behaviour. Hence, their struc-
ure characterization was ﬁrst performed by means of rheology,
hich proved the viscoelastic behaviour of CLNaHA and NaHA,
nd the viscous ﬂuid behaviour of ZnHA. According to the result
f cytotoxicity measurement, CLNaHA and NaHA were biocom-
atibile, while ZnHA displayed lower biocompatibility. Rheological
nd tensile test in vitro measurements showed their capability for
ucoadhesion. Ex vivo experiments, involving tensile test, were
lso performed, these circumstances being closer to those in the
ye, to predict the mucoadhesive behaviour on the eye surface
r in the cul-de-sac more precisely. In this case, higher adhesion
ork was measured, which predicts an increased level of interpen-
tration and chemical bond formation on the eye surface or in the
ul-de-sac.
In all cases, CLNaHA showed the highest capability for mucoad-
esion, due to its nanoparticulate structure, which can easily
nterpenetrate and form secondary bonds with the mucin. The
tructure of ZnHA hampers interpenetration, entanglement and
ond formation, which results in lower adhesive force and work
f adhesion values.
As potential drug delivery systems, SD release was  also deter-
ined. From all three derivatives, rapid release was observed in
he initial period, which is especially beneﬁcial in ocular therapy.
he advantageous rheological and mucoadhesive properties of the
erivatives ensure resistivity during blinking, which prolongs the
esidence time on the eye. Although ZnHA has weaker mucoadhe-
ive, drug release properties and lower biocompatibility in vitro,
ts application in ophthalmic formulations is favourable due to its
cavenger, bactericidal, bacteriostatic and fungicidal effects, which
llows omission of the preservative from the formulation. Conse-
uently, all three investigated derivatives can serve as potential
cular mucoadhesive drug delivery systems with an appropriate
rug release proﬁle whereby the administration frequency can be
ecreased and the patient compliance might be increased. How-
ver, the nanosized CLNaHA with its increased mucoadhesion,
ven at lower concentrations, is preferable for use in ophthalmic
reparations so as to increase the residence time of the active
gent.
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ABSTRACT
Ocular drug delivery formulations must meet anatomical, biopharmaceutical, patient-driven and regulatory
requirements. Mucoadhesive polymers can serve as a better alternative to currently available ophthalmic
formulations by providing improved bioavailability. If all requirements are addressed, a polymeric
formulation resembling the tear film of the eye might be the best solution. The optimum formulation
must not have high osmotic activity, should provide appropriate surface tension, pH and refractive index,
must be non-toxic and should be transparent and mucoadhesive. We would like to highlight the importance
of in vitro polymer testing from a pharmaceutical aspect. We, therefore, carried out physical–chemical
investigations to verify the suitability of certain systems for ophthalmic formulations. In this work, in situ
gelling, mucoadhesive thiolated poly(aspartic acid)s were tested from ophthalmic formulation aspects. The
results of preformulation measurements indicate that these polymers can be used as potential carriers in
ophthalmic drug delivery.
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Introduction
The eye is a very complex organ with several barriers. The long-term
treatment of certain eye diseases may cause adverse effects.
Unfortunately, recently marketed ophthalmic formulations have
very poor bioavailability1. Accordingly, there is an obvious need for
more efficient formulations but a number of factors must be taken
into consideration, such as anatomical and biopharmaceutical (API)
aspects, patient-driven challenges and, not least, mandatory
regulatory factors2.
The anatomy of the eye poses considerable difficulties for ocular
drug delivery. The most important anatomical barriers of the eye are
the barriers responsible for drug removal from the ocular surface
(blinking and the tear film) and the lacrimal fluid-eye barriers (the
cornea and the conjunctiva)3. The volume of a dispensed eye drop is
5–6 times greater than the tear fluid volume on the ocular surface.
During eye drop instillation, the fluid may flow out of the eye,
followed by reflex blinking and a possible increase in tear secretion,
especially if the eye drop contains an irritant4,5. Both the pH of the
drug delivery system and the osmolality of the formulation must be
similar to those of the natural tear film as otherwise the formulation
can cause increased tearing and irritation, resulting in poor
therapeutic efficiency6. The corneal surface and conjunctiva are
covered by a mucin coat, secreted by the goblet cells of the
conjunctiva, with the functions of hydration, cleaning, lubrication
and defense against pathogens. The corneal epithelium contains five
cell layers, which are very well sealed, because the cells are joined by
tight junctions and gap junctions, and they provide resistance
against both hydrophilic and lipophilic active ingredients4. Another
possibility for drug removal is the absorption of the drug into the
systemic circulation. All these processes result in low ocular
bioavailability (55%)3.
A strategy to increase the bioavailability of the API is to prolong
the residence time on the ocular surface by the application of
mucoadhesive formulations. The most recent ocular mucoadhesive
drug delivery system developments can be divided into two main
groups: the micro- or nano-sized drug deliveries7–12 and the in-situ
forming gels or films13–16.
The biopharmaceutical-driven challenges involve the hydrophili-
city or lipophilicity, the size and the charge of the API. Active agents
with an amphiphilic character have the greatest chance of
penetrating through the cornea and conjunctiva17,18. The molecular
mass of the drug and its delivery system play an important role in
the penetration19–21. The components of the tears (buffers and
proteins) must be taken into consideration during formulation of a
new ocular drug delivery system because they can bind to the active
ingredient and change its ionization state22. All these physicochem-
ical properties can affect the route and the rate of permeation in the
cornea.
The needs of patients must be satisfied by novel formulations.
The optimum drug delivery system must be effective, should require
few applications per day and should be easy to handle and dispense;
it must not cause local or systemic adverse events and only minimal
or no visual interference, no ocular discomfort or foreign body
sensation and no blockage of puncta or canaliculi; it must be as non-
invasive as possible; and it must be inexpensive2.
The regulation requirements of ophthalmic formulations have not
been as well defined as concerns drug delivery development as in
the case of solid oral dosage forms. The most important factors of
the guidelines issued by the American Society of Hospital
Pharmacists on pharmacy-prepared ophthalmic products are the
tonicity, the pH, the buffering capacity, the inherent toxicity of
the drug and the form, the need for a preservative, the solubility,
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the viscosity and the stability in an appropriate vehicle, and the
packaging and storage of the finished product23. Although the test
of these factors is not listed in the regulatory directives, the
manufacturers must fulfill them and these preformulation measure-
ments are included in the Drug Master File24. The European
Commission has issued protocols for local toxicity and eye irritation
measurements, in which the MTTQ1 assay for the rabbit corneal
epithelial (RCE) cell line is included. This test provides essential
information on the biocompatibility of the measured active
ingredient or excipients at a cellular level25.
In our work, we decided to perform physical–chemical investiga-
tions in order to verify the suitability of a system for ophthalmic
formulations. We set out to prove that an in situ gelling
mucoadhesive drug formulation, thiolated poly(aspartic acid)
(ThioPASP), meets all of the important requirements of each of
the aspects discussed above. Such formulations must spread on the
corneal surface or in the cul-de-sac and provide a short gelation
time, their pH must be 7.4, they must be isotonic and non-toxic
and they must not cause visual interference (appropriate refractive
index and transmittance)26.
PASP has been proven to be biocompatible and biodegradable,
thanks to its protein-like structure. It is not toxic and does not
generate immunogenicity, but the biocompatibility of ThioPASP as a
novel derivative must be investigated carefully. ThioPASP is redox-
sensitive and in situ gelling16,27,28. We determined the pH,
osmolality, surface tension, refractive index, transmittance and
toxicity of polymer solutions and the mucoadhesion and rheological
parameters of the gels obtained from the polymer solutions.
Materials and methods
Materials
Previously synthetized ThioPASP (Mw 12–14 kDa, thiolated to an
extent of 10% n/n) was characterized from ophthalmic biopharma-
ceutical aspects16–28. Polymer solutions were prepared with distilled
water or phosphate buffer solution (pH 7.4). A phosphate-buffered
saline (PBS) solution of pH 7.4 was prepared by dissolving 8 g dm3
NaCl, 0.2 g dm3 KCl, 1.44 g dm3 Na2HPO4.2H2O and 0.12 g dm
3
KH2PO4 in distilled water, the pH being adjusted with 0.1 M HCl.
Mucin (porcine gastric mucin type II) for mucoadhesion measure-
ments, MTT (3–(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) and dimethyl sulfoxide (DMSO) for cytotoxicity determina-
tion were purchased from Sigma-Aldrich (St. Louis, MOQ2 ). 1 M NaBrO3
solution was used as a model oxidant to facilitate the gelation of
ThioPASP.
Methods
Osmolality, surface tension, refractive index and pH determination
Osmolality, surface tension and refractive index were measured in
aqueous solutions of ThioPASP at five concentrations (1, 3, 5, 7 and
10% w/w).
Osmolality measurements were carried out with an automatic
osmometer (Knauer Semi-micro Osmometer, Berlin, GermanyQ2 ) in
three parallels. The osmolality of a solution was determined by
measurement of the freezing point depression of the solution. One
hundred and fifty microliters of the solution in the test tube was
placed into the instrument. In the first segment of the measure-
ment, the sample was overcooled, to a temperature lower than its
freezing point. In the second segment, mixing was applied, which
promoted crystallization of the sample. During the crystallization,
the temperature automatically rose to the freezing point of the
sample and remained at that temperature for a while. The
osmolality (in mOsmol/l) of the sample was calculated from the
freezing point depression.
Surface tension measurements were performed in 10 parallels
with the OCA Contact Angle System (Dataphysics OCA 20,
Dataphysics Inc., GmbH, Germany), using the pendant drop
method. The Young–Laplace equation was used for the calculation
of surface tension29.
Refractive index was measured with an Abbe-type refractometer.
The pH of the ThioPASP solutions prepared with distilled water
and PBS was determined with a pH-meter (Testo 206-pH2, UK Q3).
Optical test
Optical tests were performed by the measurement of transmittance
with a UV-spectrophotometer (Unicam Helios a Thermospectronic
UV-spectrophotometer v4.55, UK Q3) in the wavelength range 200–
600 nm. Transmittance was determined in aqueous solutions of
ThioPASP at five concentrations (1, 3, 5, 7 and 10% w/w).
Cytotoxicity measurement
Cytotoxicity measurements were performed by means of the MTT
assay. In living cells, cellular reducing agents and dehydrogenase
reduce the dye MTT (yellow) to its insoluble form, formazan (purple).
RCE cells were seeded in 96-well plates with an area of 0.34 cm2 at a
density of 105 cells cm2 and incubated at 37 C in an atmosphere
of 5% CO2 for 24 h. ThioPASP solutions were measured in
concentrations of 5, 7 and 10% w/w. The samples were kept in
contact with the cells for 3 h and then removed. The cells were
subsequently treated with 50 ml MTT at 0.25 g ml1 and 150 ml
Hank’s buffered salt solution (HBSS)(pH 7.4) and incubated for 3 h at
37 C under 5% CO2. At the end of this incubation time, the MTT was
aspirated off and the cells were washed with HBSS, and 100 ml/well
of DMSO was added in order to break the cell membrane to allow
solubilization and the release of formazan crystals formed by the
enzymatic conversion (mitochondrial dehydrogenase) of MTT. The
absorbance of formazan solutions was assayed at 570 nm with an
ELISA plate reader (Microplate Absorbance ReaderiMARKTM, Bio-Rad
Laboratories Srl, Segrate, Italy Q2), with the reference wavelength set at
690 nm after vigorous shaking for 60 s. Cell viability was calculated
as the percentage ratio of the absorbance of each sample and the
absorbance of the cells kept in contact with HBSS (control). Eight
replicates were performed for each sample30–32.
Rheology
Rheological measurements were carried out with a Physica MCR101
rheometer (Anton Paar, Graz, Austria Q2). The measuring device was of
the cone and plate type (diameter 25mm, gap height at the middle
of the cone 0.046mm and cone angle 1). ThioPASP was dissolved in
PBS and gelation was initiated by the addition of oxidizing agent
(20% w/w) on the plate of the rheometer (final ThioPASP
concentrations 5, 7 and 10% w/w). For the mucoadhesive
investigation, the polymer solutions were mixed with mucin (final
mucin concentration in the mixtures 5% w/w). The gelation of the
ThioPASP polymer was followed at a constant angular frequency of
1.0 s1 and at a constant strain of 1% at 25 C. Measurements were
carried out on freshly-made samples and were started immediately
after the mixing of the compositions. The viscoelastic character was
determined by frequency sweep tests after the total gelation, with a
strain of 1% at 25 C. Storage modulus (G’) and loss modulus (G00)
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were determined over the angular frequency range from 0.1 to
100 1s1. The strain value (1%) used in the measurements was in the
range of the linear viscoelasticity of the gels16. In order to
investigate the effect of blinking on the gel structure, accelerated
blinking cycles were applied by using the automation function of
the instrument. Tests were performed at 10% w/w ThioPASP. One
blinking cycle comprises three sections: the strain section (with a
strain of 2000%, a frequency of 0.50Hz and a duration of 30 s)
corresponding to blinking; followed by the rest section for 1 min
and finally the measurement of G’ and G00 at low strain value (a
constant strain of 1% and a frequency of 1Hz). The cycles were
repeated until constant moduli values were attained; in our case,
13 loops were used.
Results and discussion
Osmolality, surface tension, refractive index and pH
determination
In the event of ocular drug delivery formulation, it is necessary to
take the physiological properties of the tear film into consideration,
such as pH (7.4), osmolality (310–350 mOsmol kg1), surface tension
(44mN m1) and refractive index (male: 1.3368; female: 1.3371)1,33.
During ocular drug delivery formulation, several excipients are
used which can change the physical and chemical properties of the
ocular surface and the stability of the tear film34. Surfactants are able
to change the surface tension of the tear and the permeability of the
epithelial membranes, resulting in increases in the solubility of the
drugs and the drug uptake.
In a hyperosmotic tear environment, water flows out of the cells
to balance the osmolality of the intracellular fluids and the
surrounding tears. In this case, the cells in the ocular surface
become dehydrated, damaging the cell membranes.
Hypoosmolality is well tolerated by patients, but if it is very low it
can cause irritation of the eye.
Eye drops of pH 6–9 do not cause discomfort, but outside this
range an increased production of tear fluid due to irritation can be
observed35,36.
We determined the osmolality, surface tension and refractive
index at five concentrations. The results are shown in Table 1.
The results revealed that the polymer has a very low osmotic
activity. The increase of the polymer concentration resulted in an
increase in osmolality, but this was not of great significance. These
values are beneficial: after the osmolality of the eye drops has been
set with an isotonizing agent, the ThioPASP will not result in a
hyperosmotic solution (thanks to its low osmotic activity) that can
cause cell damage.
The measured surface tension and refractive index values differ
slightly from those of water (71.99 ± 0.05mN m1 and 1.3330,
respectively)37. The increase of the polymer concentration did not
influence the surface tension, but the refractive index increased to a
small extent. Thus, ThioPASP solutions do not lower the surface
tension of the tears, leading to irritation, and do not cause visual
interference.
The pH of the ThioPASP solution prepared with distilled water or
with PBS was 5.4 and 7.4, respectively. For eye drop formulation,
therefore ThioPASP solution should be prepared in the buffer so as
to meet the pH requirements necessary to avoid irritation.
The osmolality, surface tension, refractive index and pH
measurement results indicate that ThioPASP may be a very
promising eye drop formulation. Thanks to its inert properties,
ThioPASP solution does not affect the tear stability and the
ophthalmic requirements can be achieved through the addition of
necessary excipients such as the isotonizing and surface tension
modifying agents.
Optical test
Side effects influencing a patient’s vision can reduce their will-
ingness to take their medication. Thus, ocular drug delivery systems
must not cause a feeling of sand in the eyes, dry eye or blurry
vision38,39. The transmittance spectrum of ThioPASP was, therefore,
measured in order to characterize the possible effects of the
solution on the vision (Figure 1).
The spectral transmittance curve reveals that ThioPASP solutions
are transparent in visible light, which means that they will not cause
any visual disturbance. The increase of the polymer concentration
resulted in a shift of the curves toward longer wavelength, but even
at the highest concentration the polymer solution does not have
any effect on vision.
Cytotoxicity
Ocular toxicity depends on the concentration of the material used,
the frequency of application and the rate of removal40. Possible
irritation of the eye can be determined very sensitively by means of
the MTT assay41.
Cytotoxicity measurements were performed with the MTT assay
on the RCE cell line. Only the viable cells are able to reduce the dye
MTT to formazan. Figure 2 shows the viability of cells after contact
with ThioPASP solution samples relative to control cells.
The results demonstrate that ThioPASP solution is biocompatible
because the cell viability was490% after a contact time of 3 h in all
cases. This is an extremely important finding, especially because RCE
cells are very sensitive so that it can be predicted that ThioPASP
solution will highly probably not have a toxic effect on the eye.
Rheology
In order to investigate the structure of the gels formed, rheological
methods were used. As the systems gel in situ, the gelation time and
the gel structure were first analyzed by means of oscillation tests.
The systems were studied both in the absence and in the presence
of mucin; the latter situation imitated the possible in vivo interaction
of the polymer and the mucus layer of the eye.
Table 2 lists the gelation times with and without mucin. The
gelation time can be taken as the time at which a maximum is
observed in the curve of the differential with respect to time16.
It is clear that, whereas no gelation occurred at 5% w/w polymer
concentration, at higher concentrations the gelation was faster and
a stronger gel structure was formed (higher G’ values) in the
presence of mucin (Table 2). The gelation time decreased on the
increase of the polymer concentration. These results predict faster
gelation during in vivo application in the eye, which is very
beneficial, because the gelation time can be decreased and a
stronger gel structure may evolve.
Table 1. Measured values of osmolality, surface tension and refractive index.
Concentration
(% w/w)
Osmolality
(mOsm/l)
Mean± SD
Surface
tension (mN/m)
Mean± SD Refractive index
1 4.3 ± 0.5 75.3 ± 0.3 1.3330
3 8.0 ± 0.0 75.4 ± 0.3 1.3330
5 11.0 ± 1.6 75.3 ± 0.2 1.3332
7 17.0 ± 2.2 75.4 ± 0.1 1.3339
10 19.3 ± 0.5 75.4 ± 0.2 1.3342
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The adhesion between the ocular formulation and the eye tissues
is very beneficial, because such formulations provide better
bioavailability; a lower API concentration and a lower administration
frequency are sufficient for effective therapy because of the
increased residence time42–45.
The next important step was to perform the frequency sweep
test on ThioPASP gels with and without mucin (Figure 3).
At higher polymer concentrations (7 and 10% w/w), G’ proved to
be independent of the frequency, which indicates strong chemical
interactions between the polymer chains and a strong gel structure.
Figure 3 shows that mucin led to a higher G’, revealing the
interaction between the mucin and the polymer. The most marked
difference was at a polymer concentration of 5% w/w, while at 7 and
10% w/w ThioPASP stronger gel structure hindered interpenetration
between the mucin and the polymer chains. The process of
mucoadhesion involves interpenetration and chemical bond forma-
tion, leading to the increase of G’16.
During the formulation of a mucoadhesive ocular drug delivery
system, eye movements and blinking must be taken into
consideration, because the gel on the surface of the eye is exposed
to a continuous shear force, which may thin or dislodge the
formulation46. As a result, the gel structure may be disrupted under
this shear. The strength of the gel was investigated in cycling strain
tests, simulating the real circumstances in the eye. One blinking
cycle can correspond to 1 min of blinking.
Figure 4 depicts the changes in the structure during the blinking
cycles. It can be observed that the moduli decreased only in the first
two cycles and later became practically constant. The form applied
Figure 1. Spectral transmittance curve of ThioPASP solution at five concentrations.
Figure 3. Frequency sweep test of 10% w/w ( ), 7% w/w ( ) and 5% w/w ( )
ThioPASP gels with (filled symbols) and without mucin (empty symbols).
Figure 2. Cell viability after contact with ThioPASP solutions.
Table 2. Gelation time determination.
Gelation time (s)
ThioPASP concentration
(% w/w) Without mucin With mucin
5 n.g. n.g.
7 780 600
10 360 300
n.g., no gelation.
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to the eye surface remained in a gel state during blinking, as indicated
by the constant phase moduli. The large G’ value and the difference
between the moduli indicated the presence of the gel structure,
which preserved its strength after several test cycles. There was no
difference between the shapes of the curves in the cases of mucin-
containing and mucin-free samples. The only difference was in the
value of G’; the mucin-containing sample gave higher values, the
mucoadhesivity being maintained under shear.
The rheological measurements showed that the ThioPASP gels
retained their gel state during blinking, and also their mucoadhe-
sivity. This advantageous property plays an important role in the
increase of bioavailability by prolonging the residence time of the
formulation on the ocular surface.
Conclusion
ThioPASP was characterized from ophthalmic formulation aspects.
Preformulation measurements were performed (osmolality, surface
tension, refractive index, transmittance and cytotoxicity) and on gels
(rheological parameters, effects of blinking and mucoadhesion) in
order to verify the suitability of these polymers for ophthalmic
formulations. The results demonstrated that ThioPASP solutions are
biocompatible and will not cause blurred vision. During eye drop
formulation, ThioPASP facilitates adjustment of the optimum
solution properties with other excipients (buffer, isotonizing agent,
etc.), because it does not have a significant effect on the osmolality,
refractive index, surface tension or pH. ThioPASP gels are resistant
against blinking and, thanks to their mucoadhesive property, the
bioavailability of the formulation can increase, leading to a decrease
in administration frequency and, therefore, better patient compli-
ance. Consequently, ThioPASP polymers are appropriate carriers in
ophthalmic drug delivery formulations thanks to their biocompat-
ibility, stable gel structure, inertness and mucoadhesive properties.
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